Original Article
IDH1 and IDH2 Mutations in Gliomas
N Engl J Med 2009; 360:765-773February 19, 2009
- Abstract
Background
A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of such tumors, most frequently in tumors that were known to have evolved from lower-grade gliomas (secondary glioblastomas).
Methods
We determined the sequence of the IDH1 gene and the related IDH2 gene in 445 central nervous system (CNS) tumors and 494 non-CNS tumors. The enzymatic activity of the proteins that were produced from normal and mutant IDH1 and IDH2 genes was determined in cultured glioma cells that were transfected with these genes.
Results
We identified mutations that affected amino acid 132 of IDH1 in more than 70% of WHO grade II and III astrocytomas and oligodendrogliomas and in glioblastomas that developed from these lower-grade lesions. Tumors without mutations in IDH1 often had mutations affecting the analogous amino acid (R172) of the IDH2 gene. Tumors with IDH1 or IDH2 mutations had distinctive genetic and clinical characteristics, and patients with such tumors had a better outcome than those with wild-type IDH genes. Each of four tested IDH1 and IDH2 mutations reduced the enzymatic activity of the encoded protein.
Conclusions
Mutations of NADP+-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur in a majority of several types of malignant gliomas.
Media in This Article
Figure 1
IDH1 and IDH2 Mutations in Human Gliomas.Figure 2
Enzymatic Activity of Wild-Type and Mutant IDH1 and IDH2 Proteins.Article Activity
- Article
Gliomas, the most common type of primary brain tumors, are classified as grade I to grade IV on the basis of histopathological and clinical criteria established by the World Health Organization (WHO).1 This group of tumors includes specific histologic subtypes, the most common of which are astrocytomas, oligodendrogliomas, and ependymomas. WHO grade I gliomas, often considered to be benign, are generally curable with complete surgical resection and rarely, if ever, evolve into higher-grade lesions.2 By contrast, gliomas of WHO grade II or III are invasive, progress to higher-grade lesions, and have a poor outcome. WHO grade IV tumors (glioblastomas), the most invasive form, have a dismal prognosis.3,4 On the basis of histopathological criteria, it is impossible to distinguish a secondary glioblastoma, defined as a tumor that was previously diagnosed as a lower-grade glioma, from a primary tumor.5,6
Several genes, including TP53, PTEN, CDKN2A, and EGFR, are altered in gliomas.7-12 These alterations tend to occur in a defined order during the progression to a high-grade tumor. The TP53 mutation appears to be a relatively early event during the development of an astrocytoma, whereas the loss or mutation of PTEN and amplification of EGFR are characteristic of higher-grade tumors.6,13,14 In oligodendrogliomas, allelic losses of 1p and 19q occur in many WHO grade II tumors, whereas losses of 9p21 are largely confined to WHO grade III tumors.15
In a recent genomewide analysis, we identified somatic mutations at codon 132 of the isocitrate dehydrogenase 1 gene (IDH1) in approximately 12% of glioblastomas.16 These mutations were also found in five of six secondary glioblastomas. The results suggested that IDH1 mutations might occur after formation of a low-grade glioma and drive the progression of the tumor to a glioblastoma. To evaluate this possibility, we analyzed a large number of gliomas of various types.
Methods
DNA Samples
DNA was extracted from samples of primary brain tumor and xenografts and from patient-matched normal blood lymphocytes obtained from the Tissue Bank at the Preston Robert Tisch Brain Tumor Center at Duke University and collaborating centers, as described previously.17 All analyzed brain tumors were subjected to consensus review by two neuropathologists. Table 1Table 1
Summary of Genetic and Clinical Characteristics of Brain Tumors in the Study. lists the types of brain tumors we analyzed. The samples from glioblastomas included 138 primary tumors and 13 secondary tumors. Of the 138 primary tumors, 15 were from patients under the age of 21 years. Secondary glioblastomas were categorized as WHO grade IV on the basis of histologic criteria but had been categorized as WHO grade II or III at least 1 year earlier. Of the 151 tumors, 63 had been analyzed in our previous genomewide mutation analysis of glioblastomas. None of the lower-grade tumors were included in that analysis.16 In addition to brain tumors, we analyzed 35 lung cancers, 57 gastric cancers, 27 ovarian cancers, 96 breast cancers, 114 colorectal cancers, 95 pancreatic cancers, and 7 prostate cancers, along with 4 samples from patients with chronic myelogenous leukemia, 7 from patients with chronic lymphocytic leukemia, 7 from patients with acute lymphoblastic leukemia, and 45 from patients with acute myelogenous leukemia. All samples were obtained in accordance with the Health Insurance Portability and Accountability Act. Acquisition of tissue specimens was approved by the institutional review board at the Duke University Health System and at each of the participating institutions.
Exon 4 of the IDH1 gene was amplified with the use of a polymerase-chain-reaction (PCR) assay and sequenced in DNA from the tumor and lymphocytes from each patient, as described previously.16 In all gliomas and medulloblastomas without an R132 IDH1 mutation, exon 4 of the IDH2 gene (which contains the IDH2 residue equivalent to R132 of IDH1) was sequenced and analyzed for somatic mutations. In addition, we evaluated all astrocytomas and oligodendrogliomas of WHO grade I to grade III, all secondary glioblastomas, and 96 primary glioblastomas without R132 IDH1 mutations or R172 IDH2 mutations for alterations in the remaining coding exons of IDH1 and IDH2. All coding exons of TP53 and PTEN were also sequenced in the panel of diffuse astrocytomas, oligodendrogliomas, anaplastic oligodendrogliomas, anaplastic astrocytomas, and glioblastomas. EGFR amplification and the CDKN2A–CDKN2B deletion were analyzed with the use of quantitative real-time PCR in the same tumors.18 We evaluated samples of oligodendrogliomas and anaplastic oligodendrogliomas for loss of heterozygosity at 1p and 19q, as described previously.15,19
Enzymatic Activity
To assess the enzymatic activity of wild-type and mutant IDH1 and IDH2 proteins, a human oligodendroglioma line without IDH1 or IDH2 mutations was transfected with a vector (pCMV6, Invitrogen) containing the coding sequences of the wild-type IDH1, wild-type IDH2, or mutant IDH genes (corresponding to the most common IDH1 mutation, R132H, or the IDH2 mutations R172G, R172K, and R172M). Clones of the wild-type IDH1 and IDH2 genes were obtained from Origene, and mutations were introduced by standard methods.
Cells were collected 48 hours after transfection, subjected to centrifugation at 1000×g for 10 minutes at 4°C, washed once with cold phosphate-buffered saline, and lysed in buffer containing 0.1% Triton X-100. They were then disrupted by ultrasonication and centrifuged at 12,000×g for 30 minutes. The supernatants were used to measure IDH activity. Expression levels of wild-type and mutant IDH proteins were determined by Western blotting with the use of an antibody against FLAG, a polypeptide protein tag. For each enzymatic reaction, a volume of cell lysate containing the same amount of IDH protein was added to 1 ml of assay solution containing 33 mM of Tris buffer, 0.33 mM of EDTA, 0.1 mM of NADP+, 1.33 mM of manganese chloride, and 1.3 mM of isocitrate. The activity of IDH was analyzed through the reduction of NADP+ to NADPH, which was measured at 25°C by spectrophotometry at 340 nm 5 times a second for 300 seconds.20
Clinical Data and Survival
Clinical information included the date of birth, the date the study sample was obtained, the date of pathological diagnosis, the date and pathology of any preceding diagnosis of a lower-grade glioma, the use or nonuse of radiation therapy or chemotherapy before the date that the study sample was obtained, the date of the last contact with the patient, and the patient's status at the time of the last contact. We calculated overall survival for patients with anaplastic astrocyomas, including 38 patients with mutations in IDH1 or IDH2 and 14 with wild-type genes, and for adult patients (≥21 years of age) with glioblastomas, including 14 patients with mutations in IDH1 or IDH2 and 115 with wild-type genes, using the date of histologic diagnosis and the date of the last contact with the patient or death. For patients with secondary glioblastomas, survival was calculated from the date of secondary diagnosis. Seven patients with glioblastomas were not included in the statistical analysis because of insufficient survival data.
Study Design
The authors designed the study, gathered and analyzed the data, wrote the manuscript, and made the decision to publish the findings. Gene sequencing was performed by Agencourt Bioscience, a subsidiary of Beckman Coulter. The lead academic authors vouch for the completeness and accuracy of the data and the analyses.
Statistical Analysis
We examined the association between the occurrence of mutations in IDH1 or IDH2 and other genetic alterations using Fisher's exact test. Kaplan–Meier survival curves were plotted and the survival distributions were compared with the use of the Mantel–Cox log-rank test and the Wilcoxon test. All reported P values are two-sided, and P values of less than 0.01 were considered to indicate statistical significance.
Results
Sequence Analysis
Sequence analysis of IDH1 in 939 tumor samples revealed 161 somatic mutations at residue R132, including R132H (142 tumors), R132C (7 tumors), R132S (4 tumors), R132L (7 tumors), and R132G (1 tumor) (Figure 1AFigure 1
IDH1 and IDH2 Mutations in Human Gliomas.; and Fig. 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). Table 1 and Figure 1B show the tumors with somatic R132 mutations. No other somatic mutations of IDH1 in the remaining IDH1 exons of R132-negative tumors were found in all WHO grade I to grade III astrocytomas and oligodendrogliomas, in all secondary glioblastomas, and in 96 primary glioblastomas. No R132 mutations were observed in 21 pilocytic astrocytomas (WHO grade I), 2 subependymal giant-cell astrocytomas (WHO grade I), 30 ependymomas (WHO grade II), 55 medulloblastomas, or any of the 494 non–central nervous system tumor samples.We also sought alterations in other genes with functions similar to those of IDH1 in tumors without IDH1 mutations. For this purpose, we analyzed the IDH2 gene, which encodes the only human protein homologous to IDH1 that uses NADP+ as an electron acceptor. Sequence evaluation of all IDH2 exons in these glioma samples revealed nine somatic mutations of IDH2, all at residue R172: R172G in two tumors, R172M in three tumors, and R172K in four tumors (Figure 1A, and Fig. 1 in the Supplementary Appendix). The R172 residue in IDH2 is the exact analogue of the R132 residue in IDH1, which is located in the active site of the enzyme and forms hydrogen bonds with the isocitrate substrate.21
To determine whether the mutations in IDH1 and IDH2 disturb the function of the corresponding proteins, we measured the enzymatic activity (reduction of NADP+ to NADPH) of IDH1 and IDH2 proteins in an oligodendroglioma line that had been transfected with wild-type or mutant IDH1 or IDH2 genes. These mutants represented 88% of the IDH1 mutations and 100% of the IDH2 mutations found in patients. Figure 2Figure 2
Enzymatic Activity of Wild-Type and Mutant IDH1 and IDH2 Proteins. shows that exogenous expression of wild-type IDH1 or IDH2 significantly increased the production of NADPH, whereas only endogenous IDH activity was observed in cells that had been transfected with mutant IDH1 or IDH2 genes.To further evaluate IDH alterations during glioma progression, we assessed IDH1 mutations in seven progressive gliomas in which both low-grade and high-grade tumor samples were available. Sequence analysis identified IDH1 mutations in both the low-grade and high-grade tumors in all seven cases (Table 1, and Fig. 2 in the Supplementary Appendix). These results demonstrate that IDH1 alterations in high-grade tumors are derived from the earlier lesions.
We also examined diffuse astrocytomas, oligodendrogliomas, anaplastic oligodendrogliomas, anaplastic astrocytomas, and a subgroup of glioblastomas for mutations in TP53 and PTEN, amplification of EGFR, deletion of CDKN2A–CDKN2B, and allelic losses of 1p and 19q (Table 1). TP53 mutations were more common in diffuse astrocytomas (74%), anaplastic astrocytomas (65%), and secondary glioblastomas (62%) than in oligodendrogliomas (16%) or anaplastic oligodendrogliomas (9%) (P<0.001 for all comparisons by Fisher's exact test). Conversely, deletions of 1p and 19q were found more often in oligodendrocytic than in astrocytic tumors, as expected.15
Most (80%) of the anaplastic astrocytomas and glioblastomas with mutated IDH1 or IDH2 genes also had a mutation of TP53, but only 3% had alterations in PTEN, EGFR, CDKN2A, or CDKN2B (Table 2Table 2
Frequency of Common Genetic Alterations in Gliomas with Mutated or Wild-Type IDH1 and IDH2 Genes.). Conversely, anaplastic astrocytomas and glioblastomas with wild-type IDH1 and IDH2 genes had few TP53 mutations (18%) and more frequent alterations of PTEN, EGFR, CDKN2A, or CDKN2B (74%) (P<0.001 for both comparisons by Fisher's exact test). Loss of 1p and 19q was observed in 45 of 53 (85%) of the oligodendrocytic tumors with mutated IDH1 or IDH2 but in none of the tumors with wild-type IDH genes (P<0.001 by Fisher's exact test).Patients with anaplastic astrocytomas or glioblastomas with IDH1 or IDH2 mutations were significantly younger than were patients with tumors carrying wild-type IDH1 and IDH2 genes (median age, 34 years vs. 56 years for patients with anaplastic astrocytomas and 32 years vs. 59 years for those with glioblastomas; P<0.001 for both comparisons by Student's t-test). Despite the lower median age of patients with IDH1 or IDH2 mutations, no mutations were identified in glioblastomas from the 15 patients who were under the age of 21 (Fig. 3 in the Supplementary Appendix). In patients with oligodendrogliomas or anaplastic oligodendrogliomas, the median age of the patients with IDH1 or IDH2 mutation was 39 years; IDH1 mutations were identified in two teenagers (14 and 16 years) but not in four younger patients.
Our previous observation of improved outcome for patients whose glioblastomas carried the IDH1 mutation16 was confirmed in this larger data set and extended to include such patients with mutations in IDH2. Patients with a glioblastoma carrying an IDH1 or IDH2 mutation had a median overall survival of 31 months, which was significantly longer than the 15-month survival in patients with wild-type IDH1 (P=0.002 by the log-rank test) (Figure 3AFigure 3
Survival of Adult Patients with Malignant Gliomas with or without IDH Gene Mutations.). Mutations of IDH genes were also associated with improved outcome in patients with anaplastic astrocytomas; the median overall survival was 65 months for patients with mutations and 20 months for those without mutations (P<0.001 by the log-rank test) (Figure 3B). Differential survival analyses could not be performed in patients with diffuse astrocytomas, oligodendrogliomas, or anaplastic oligodendrogliomas because there were too few tumors of these types without IDH gene mutations.Discussion
Our findings implicate mutations in the NADP+-dependent isocitrate dehydrogenase genes, IDH1 and IDH2, in the pathogenesis of malignant gliomas. Gliomas with IDH mutations were clinically and genetically distinct from gliomas with wild-type IDH genes. Notably, two subtypes of gliomas of WHO grade II or III (astrocytomas and oligodendrogliomas) often carried IDH mutations but not other genetic alterations that are detectable relatively early during the progression of gliomas. This finding suggests that IDH mutations occur early in the development of a glioma from a stem cell that can give rise to both astrocytes and oligodendrocytes. The identification of IDH1 mutations in 10 of 10 oligoastrocytomas and anaplastic oligoastrocytomas, tumors with morphologic features of both cell types, supports this conjecture.
Mutations in IDH1 or IDH2 were not identified in any pilocytic astrocytomas of WHO grade I, indicating that these tumors arise through a different mechanism. This conclusion is consistent with clinical observations that pilocytic astrocytomas rarely if ever undergo malignant transformation2 and with recent data indicating that a duplication at 7q34 producing a BRAF fusion gene occurs frequently in pilocytic astrocytomas but not higher-grade gliomas.22
In each of the tested mutations, the enzymatic activity of the IDH proteins was eliminated. A previous study showed that in vitro substitution of glutamate for arginine at residue 132 of IDH1 (an alteration not observed in patients) resulted in a catalytically inactive enzyme.23 Although our results demonstrate an effect of the mutations on the function of the IDH1 protein, they do not necessarily mean that the mutations are inactivating. For example, the mutant proteins that preclude the use of isocitrate as substrate could allow other, as-yet-unknown substrates to be used by the enzyme, thereby conferring a gain rather than a loss of activity. If future studies confirm this possibility, mutant IDH could become a target for therapeutic intervention.
Our results have important practical implications. Historically, glioblastomas have been divided into cancers that arise from low-grade gliomas (secondary tumors) and those without such an antecedent (primary tumors).5,6 Secondary tumors account for only 5% of all glioblastomas. The finding that IDH1 or IDH2 is mutated in the vast majority of WHO grade II or III gliomas and in the secondary glioblastomas that develop from these precursors provides a biologic explanation for this clinical categorization: tumors with mutated NADP+-dependent isocitrate dehydrogenases comprise a specific subgroup of glioblastomas.
The localization of IDH1 and IDH2 mutations to a single amino acid (R132 and R172, respectively) simplifies the use of this genetic alteration for diagnostic purposes. For example, IDH mutation tests could help distinguish pilocytic astrocytomas (WHO grade I) from diffuse astrocytomas (WHO grade II), since these lesions can sometimes be difficult to categorize solely on the basis of histopathological criteria.2
Supported by a grant from the Pediatric Brain Tumor Foundation Institute, a Damon Runyon Foundation Scholar Award, a grant from the Southeastern Brain Tumor Foundation, Alex's Lemonade Stand Foundation, a grant from the V Foundation for Cancer Research, the Virginia and D.K. Ludwig Fund for Cancer Research, the Pew Charitable Trusts, the American Brain Tumor Association, the Brain Tumor Research Fund at Johns Hopkins, grants (R01CA118822, NS20023-21, R37CA11898-34, CA121113, CA43460, CA57345, 5P50-CA-108786, 5P50-NS-20023, 5R37-CA-11898, and 2P30-CA-14236) from Beckman Coulter, and grants from the Accelerate Brain Cancer Cure Foundation.
The views expressed in this article are those of the authors and do not necessarily represent the official views of the Food and Drug Administration.
Drs. Yan, Parsons, Jones, Kinzler, Velculescu, Vogelstein, and Bigner report being eligible for royalties received by Johns Hopkins University on sales of products related to research described in this article, under licensing agreements between the university and Beckman Coulter. No other potential conflict of interest relevant to this article was reported.
Drs. Yan and Parsons contributed equally to this article.
We thank Melissa J. Ehinger, Diane L. Satterfield, Eric Lipp, Michael Leonard, Jennifer D. Funkhouser, and Patrick Killela for their assistance with the clinical information; P. Buckhaults, S. Powell, S. Kern, J. Eshleman, C. Civin, I.-M. Shih, and A. Gazdar for providing DNA from non–central nervous system cancers; and Dr. A.T. Campagnoni at the University of California, Los Angeles, for donating the human oligodendroglioma cell line.
Source Information
From the Departments of Pathology (H.Y., G.J., R.M., B.A.R., D.D.B.), Radiation Oncology (I.K., I.B.-H.), Neuro-Oncology (H.F.), and Surgery (A.F., D.R.), the Pediatric Brain Tumor Foundation Institute and the Preston Robert Tisch Brain Tumor Center; and the Cancer Statistical Center (J.H.) — all at Duke University Medical Center, Durham, NC; the Ludwig Center for Cancer Genetics and Therapeutics and the Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center (D.W.P., S.J., K.W.K., V.E.V., B.V.) and the Department of Neurosurgery, Johns Hopkins Medical Institutions (G.J.R.) — all in Baltimore; the Department of Pediatrics, Baylor College of Medicine, Houston (D.W.P.); and the Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (W.Y.).
Address reprint requests to Dr. Yan at the Department of Pathology, Pediatric Brain Tumor Foundation Institute and Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, or at yan00002@mc.duke.edu; or to Dr. Parsons at the Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, or at dwparson@txccc.org.
- References
References
1
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO classifcation of tumours of the central nervous system. 4th ed. Lyon, France: IARC Press, 2007.
2
Burger PC, Scheithauer BW, Paulus W, et al. Pilocytic astrocytoma. In: Kleihues P, Cavenee WK, eds. Pathology and genetics of tumours of the nervous system. Lyon, France: IARC Press, 2000:45-51.
3
Stupp R ,Mason WP ,van den Bent MJ , et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996
Full Text | Web of Science | Medline4
Wen PY ,Kesari S . Malignant gliomas in adults. N Engl J Med 2008;359:492-507[Erratum, N Engl J Med 2008;359:877.]
Full Text | Web of Science | Medline5
Ohgaki H ,Dessen P ,Jourde B , et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004;64:6892-6899
CrossRef | Web of Science | Medline6
Ohgaki H ,Kleihues P . Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-1453
CrossRef | Web of Science | Medline7
Cancer Genome Atlas Research Network
CrossRef | Web of Science | Medline8
Li J ,Yen C ,Liaw D , et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947
CrossRef | Web of Science | Medline9
Nigro JM ,Baker SJ ,Preisinger AC , et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-708
CrossRef | Web of Science | Medline10
Ueki K ,Ono Y ,Henson JW ,Efird JT ,von Deimling A ,Louis DN . CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150-153
Web of Science | Medline11
Wong AJ ,Bigner SH ,Bigner DD ,Kinzler KW ,Hamilton SR ,Vogelstein B . Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 1987;84:6899-6903
CrossRef | Web of Science | Medline12
Wong AJ ,Ruppert JM ,Bigner SH , et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 1992;89:2965-2969
CrossRef | Web of Science | Medline13
Furnari FB ,Fenton T ,Bachoo RM , et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683-2710
CrossRef | Web of Science | Medline14
Weber RG ,Sabel M ,Reifenberger J , et al. Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization. Oncogene 1996;13:983-994
Web of Science | Medline15
Bigner SH ,Matthews MR ,Rasheed BK , et al. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999;155:375-386
CrossRef | Web of Science | Medline16
Parsons DW ,Jones S ,Zhang X , et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-1812
CrossRef | Web of Science | Medline17
Sjoblom T ,Jones S ,Wood LD , et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-274
CrossRef | Web of Science | Medline18
Wang TL ,Diaz LA Jr ,Romans K , et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A 2004;101:3089-3094
CrossRef | Web of Science | Medline19
Reifenberger J ,Reifenberger G ,Liu L ,James CD ,Wechsler W ,Collins VP . Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-1190
Web of Science | Medline20
Batinic-Haberle I ,Benov LT . An SOD mimic protects NADP+-dependent isocitrate dehydrogenase against oxidative inactivation. Free Radic Res 2008;42:618-624
CrossRef | Web of Science | Medline21
Xu X ,Zhao J ,Xu Z , et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem 2004;279:33946-33957
CrossRef | Web of Science | Medline22
Jones DT ,Kocialkowski S ,Liu L , et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008;68:8673-8677
CrossRef | Web of Science | Medline23
Jennings GT ,Minard KI ,McAlister-Henn L . Expression and mutagenesis of mammalian cytosolic NADP+-specific isocitrate dehydrogenase. Biochemistry 1997;36:13743-13747
CrossRef | Web of Science | Medline
- Citing Articles (380)
Citing Articles
1
Motohiro Arai, Sumihito Nobusawa, Hayato Ikota, Sunao Takemura, Yoichi Nakazato. (2012) Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma. Brain Tumor Pathology
CrossRef2
Icard Philippe, Zhang Xiao-Dong, Lemoisson Edwige, Louis Marie-Hélène, Allouche Stéphane, Lincet Hubert, Poulain Laurent. (2012) Experimental results using 3-bromopyruvate in mesothelioma: in vitro and in vivo studies. Journal of Bioenergetics and Biomembranes
CrossRef3
Xiaoke Shi, Yan Zhang, Junheng Zheng, Jingxuan Pan. (2012) Reactive oxygen species in cancer stem cells. Antioxidants & Redox Signaling120208101038008
CrossRef4
Libing Song, Liping Liu, Zhiqiang Wu, Chuyong Lin, Ting Dai, Chunping Yu, Xi Wang, Jueheng Wu, Mengfeng Li, Jun Li. (2012) Knockdown of stomatin-like protein 2 (STOML2) reduces the invasive ability of glioma cells through inhibition of the NF-κB/MMP-9 pathway. The Journal of Pathology 226:3, 534-543
CrossRef5
Asahito Hama, Hideki Muramatsu, Hideki Makishima, Yuka Sugimoto, Hadrian Szpurka, Monika Jasek, Christine O’Keefe, Yoshiyuki Takahashi, Hirotoshi Sakaguchi, Sayoko Doisaki, Akira Shimada, Nobuhiro Watanabe, Koji Kato, Hitoshi Kiyoi, Tomoki Naoe, Seiji Kojima, Jaroslaw P. Maciejewski. (2012) Molecular lesions in childhood and adult acute megakaryoblastic leukaemia. British Journal of Haematology 156:3, 316-325
CrossRef6
Deepti Narasimhaiah, Catherine Miquel, Elisabeth Verhamme, Paul Desclée, Guy Cosnard, Catherine Godfraind. (2012) IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri. Neuropathology 32:1, 30-37
CrossRef7
Hideki Muramatsu, Hideki Makishima, Jaroslaw P. Maciejewski. (2012) Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: Novel Pathogenetic Lesions. Seminars in Oncology 39:1, 67-73
CrossRef8
Michael A. McDevitt. (2012) Clinical Applications of Epigenetic Markers and Epigenetic Profiling in Myeloid Malignancies. Seminars in Oncology 39:1, 109-122
CrossRef9
Robert L Yauch, Jeff Settleman. (2012) Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Current Opinion in Genetics & Development
CrossRef10
Dania Daye, Kathryn E. Wellen. (2012) Metabolic Reprogramming in Cancer: Unraveling the Role of Glutamine in Tumorigenesis. Seminars in Cell & Developmental Biology
CrossRef11
Jeremy Schwartzentruber, Andrey Korshunov, Xiao-Yang Liu, David T. W. Jones, Elke Pfaff, Karine Jacob, Dominik Sturm, Adam M. Fontebasso, Dong-Anh Khuong Quang, Martje Tönjes, Volker Hovestadt, Steffen Albrecht, Marcel Kool, Andre Nantel, Carolin Konermann, Anders Lindroth, Natalie Jäger, Tobias Rausch, Marina Ryzhova, Jan O. Korbel, Thomas Hielscher, Peter Hauser, Miklos Garami, Almos Klekner, Laszlo Bognar, Martin Ebinger, Martin U. Schuhmann, Wolfram Scheurlen, Arnulf Pekrun, Michael C. Frühwald, Wolfgang Roggendorf, Christoph Kramm, Matthias Dürken, Jeffrey Atkinson, Pierre Lepage, Alexandre Montpetit, Magdalena Zakrzewska, Krzystof Zakrzewski, Pawel P. Liberski, Zhifeng Dong, Peter Siegel, Andreas E. Kulozik, Marc Zapatka, Abhijit Guha, David Malkin, Jörg Felsberg, Guido Reifenberger, Andreas von Deimling, Koichi Ichimura, V. Peter Collins, Hendrik Witt, Till Milde, Olaf Witt, Cindy Zhang, Pedro Castelo-Branco, Peter Lichter, Damien Faury, Uri Tabori, Christoph Plass, Jacek Majewski, Stefan M. Pfister, Nada Jabado. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:7384, 226-231
CrossRef12
Changho Choi, Sandeep K Ganji, Ralph J DeBerardinis, Kimmo J Hatanpaa, Dinesh Rakheja, Zoltan Kovacs, Xiao-Li Yang, Tomoyuki Mashimo, Jack M Raisanen, Isaac Marin-Valencia, Juan M Pascual, Christopher J Madden, Bruce E Mickey, Craig M Malloy, Robert M Bachoo, Elizabeth A Maher. (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nature Medicine
CrossRef13
Fonnet E. Bleeker, Remco J. Molenaar, Sieger Leenstra. (2012) Recent advances in the molecular understanding of glioblastoma. Journal of Neuro-Oncology
CrossRef14
Dakeun Lee, So Young Kang, Yeon-Lim Suh, Ji Yun Jeong, Jung-Il Lee, Do-Hyun Nam. (2012) Clinicopathologic and genomic features of gliosarcomas. Journal of Neuro-Oncology
CrossRef15
Monika E. Hegi, Robert-Charles Janzer, Wanyu L. Lambiv, Thierry Gorlia, Mathilde C. M. Kouwenhoven, Christian Hartmann, Andreas Deimling, Danielle Martinet, Nathalie Besuchet Schmutz, Annie-Claire Diserens, Marie-France Hamou, Pierre Bady, Michael Weller, Martin J. den Bent, Warren P. Mason, René-Olivier Mirimanoff, Roger Stupp, Karima Mokhtari, Pieter Wesseling. (2012) Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathologica
CrossRef16
J. Ding, A. Bashashati, A. Roth, A. Oloumi, K. Tse, T. Zeng, G. Haffari, M. Hirst, M. A. Marra, A. Condon, S. Aparicio, S. P. Shah. (2012) Feature-based classifiers for somatic mutation detection in tumour-normal paired sequencing data. Bioinformatics 28:2, 167-175
CrossRef17
Niklas Thon, Sabina Eigenbrod, Simone Kreth, Juergen Lutz, Joerg-Christian Tonn, Hans Kretzschmar, Aurelia Peraud, Friedrich-Wilhelm Kreth. (2012) IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 118:2, 452-460
CrossRef18
O. C. Andronesi, G. S. Kim, E. Gerstner, T. Batchelor, A. A. Tzika, V. R. Fantin, M. G. Vander Heiden, A. G. Sorensen. (2012) Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy. Science Translational Medicine 4:116, 116ra4-116ra4
CrossRef19
P. Metellus, D. Figarella-Branger. (2012) Magnetic Resonance Metabolic Imaging of Glioma. Science Translational Medicine 4:116, 116ps1-116ps1
CrossRef20
A. Elkhaled, L. E. Jalbert, J. J. Phillips, H. A. I. Yoshihara, R. Parvataneni, R. Srinivasan, G. Bourne, M. S. Berger, S. M. Chang, S. Cha, S. J. Nelson. (2012) Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas. Science Translational Medicine 4:116, 116ra5-116ra5
CrossRef21
Yuko Tanaka, Sumihito Nobusawa, Shinichi Yagi, Hayato Ikota, Hideaki Yokoo, Yoichi Nakazato. (2012) Anaplastic oligodendroglioma with ganglioglioma-like maturation. Brain Tumor Pathology
CrossRef22
Michael Gundry, Jan Vijg. (2012) Direct mutation analysis by high-throughput sequencing: From germline to low-abundant, somatic variants. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 729:1-2, 1-15
CrossRef23
M. Beatriz S. Lopes, Bernd W. Scheithauer. 2012. Histopathology of brain tumors. , 138-187.
CrossRef24
Shani Mulholland, Danita M. Pearson, Rifat A. Hamoudi, Deborah S. Malley, Caroline M. Smith, Jamie M.J. Weaver, David T.W. Jones, Sylvia Kocialkowski, L. Magnus Bäcklund, V. Peter Collins, Koichi Ichimura. (2012) MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. International Journal of Cancern/a-n/a
CrossRef25
Siân Jones, Meng Li, D. Williams Parsons, Xiaosong Zhang, Jelle Wesseling, Petra Kristel, Marjanka K. Schmidt, Sanford Markowitz, Hai Yan, Darell Bigner, Ralph H. Hruban, James R. Eshleman, Christine A. Iacobuzio-Donahue, Michael Goggins, Anirban Maitra, Sami N. Malek, Steve Powell, Bert Vogelstein, Kenneth W. Kinzler, Victor E. Velculescu, Nickolas Papadopoulos. (2012) Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Human Mutation 33:1, 100-103
CrossRef26
Richard Byers, Jason L. Hornick, Eleni Tholouli, Jeffery Kutok, Scott J. Rodig. (2012) Detection of IDH1 R132H Mutation in Acute Myeloid Leukemia by Mutation-specific Immunohistochemistry. Applied Immunohistochemistry & Molecular Morphology 20:1, 37-40
CrossRef27
Felix Sahm, David Capper, Stefan Pusch, Jörg Balss, Arend Koch, Claus-Dieter Langhans, Jürgen G. Okun, Andreas von Deimling. (2012) Detection of 2-Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry. Brain Pathology 22:1, 26-31
CrossRef28
Katja Tuononen, Olli Tynninen, Virinder Kaur Sarhadi, Anne Tyybäkinoja, Mikael Lindlöf, Miia Antikainen, Juha Näpänkangas, Ari Hirvonen, Hanna Mäenpää, Anders Paetau, Sakari Knuutila. (2012) The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas-correlation with array comparative genome hybridization results and IDH1 mutation. Genes, Chromosomes and Cancer 51:1, 20-29
CrossRef29
Alexandra Borodovsky, Meghan J. Seltzer, Gregory J. Riggins. (2012) Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2. Current Opinion in Oncology 24:1, 83-89
CrossRef30
Stephen Damato, Mohammed Alorjani, Fiona Bonar, Stanley W McCarthy, Stephen R Cannon, Paul O’Donnell, Roberto Tirabosco, M Fernanda Amary, Adrienne M Flanagan. (2012) IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. Histopathology 60:2, 363-365
CrossRef31
Amir T. Fathi, Omar Abdel-Wahab. (2012) Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted Therapy. Advances in Hematology 2012, 1-12
CrossRef32
Jing Li, Erik Sulman, Kenneth Aldape. 2012. Molecular biology of brain tumors. , 23-34.
CrossRef33
Akitake Mukasa, Shunsaku Takayanagi, Kuniaki Saito, Junji Shibahara, Yusuke Tabei, Kazuhide Furuya, Takafumi Ide, Yoshitaka Narita, Ryo Nishikawa, Keisuke Ueki, Nobuhito Saito. (2012) Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Cancer Scienceno-no
CrossRef34
Philippe Icard, Laurent Poulain, Hubert Lincet. (2012) Understanding the central role of citrate in the metabolism of cancer cells. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1825:1, 111-116
CrossRef35
Atom Sarkar, E. Antonio Chiocca. 2012. Glioblastoma and malignant astrocytoma. , 384-407.
CrossRef36
C Muñoz-Pinedo, N El Mjiyad, J-E Ricci. (2012) Cancer metabolism: current perspectives and future directions. Cell Death and Disease 3:1, e248
CrossRef37
Jen-Yang Tang, Chun-Chi Chang, Pei-Chin Lin, Jan-Gowth Chang. (2012) Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer. The Kaohsiung Journal of Medical Sciences
CrossRef38
Jethro Hu, Santosh Kesari. (2012) The Molecular Basis for Novel Therapies. The Cancer Journal 18:1, 32-39
CrossRef39
Michael Weller, Roger Stupp, Monika Hegi, Wolfgang Wick. (2012) Individualized Targeted Therapy for Glioblastoma. The Cancer Journal 18:1, 40-44
CrossRef40
Jiangbing Zhou, Kofi-Buaku Atsina, Benjamin T. Himes, Garth W. Strohbehn, W. Mark Saltzman. (2012) Novel Delivery Strategies for Glioblastoma. The Cancer Journal 18:1, 89-99
CrossRef41
Siyuan Zheng, Milan G. Chheda, Roel G.W. Verhaak. (2012) Studying a Complex Tumor. The Cancer Journal 18:1, 107-114
CrossRef42
Eric K. Oermann, Jing Wu, Kun-Liang Guan, Yue Xiong. (2012) Alterations of Metabolic Genes and Metabolites in Cancer. Seminars in Cell & Developmental Biology
CrossRef43
Yuejun Fu, Shuhua Zheng, Yali Zheng, Rui Huang, Na An, Aihua Liang, Changchen Hu. (2012) Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance. The International Journal of Biochemistry & Cell Biology
CrossRef44
Iris Elens, Steven De Vleeschouwer, Femke Pauwels, Stefaan Van Gool. (2012) Resection and Immunotherapy for Recurrent Grade III Glioma. ISRN Immunology 2012, 1-9
CrossRef45
N. Kijima, N. Hosen, N. Kagawa, N. Hashimoto, A. Nakano, Y. Fujimoto, M. Kinoshita, H. Sugiyama, T. Yoshimine. (2011) CD166/Activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion. Neuro-Oncology
CrossRef46
H. A. Luchman, O. D. Stechishin, N. H. Dang, M. D. Blough, C. Chesnelong, J. J. Kelly, S. A. Nguyen, J. A. Chan, A. M. Weljie, J. G. Cairncross, S. Weiss. (2011) An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro-Oncology
CrossRef47
Shinji Yamashita, Shinitsu Ryu, Shiro Miyata, Syunrou Uchinokura, Kiyotaka Yokogami, Hisao Uehara, Sayaka Moriguchi, Takashi Iwakiri, Kousuke Marutsuka, Makoto Ikenoue, Daisuke Sawa, Naoshi Yamada, Yuki Kodama, Hideo Takeshima. (2011) A huge intraventricular congenital anaplastic astrocytoma: case report with histopathological and genetic consideration. Brain Tumor Pathology
CrossRef48
Philippe Metellus, Carole Colin, David Taieb, Eric Guedj, Isabelle Nanni-Metellus, Andre Maues Paula, Cécile Colavolpe, Stephane Fuentes, Henry Dufour, Marylin Barrie, Olivier Chinot, L’Houcine Ouafik, Dominique Figarella-Branger. (2011) IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. Journal of Neuro-Oncology 105:3, 591-600
CrossRef49
L. V. Sequist, R. S. Heist, A. T. Shaw, P. Fidias, R. Rosovsky, J. S. Temel, I. T. Lennes, S. Digumarthy, B. A. Waltman, E. Bast, S. Tammireddy, L. Morrissey, A. Muzikansky, S. B. Goldberg, J. Gainor, C. L. Channick, J. C. Wain, H. Gaissert, D. M. Donahue, A. Muniappan, C. Wright, H. Willers, D. J. Mathisen, N. C. Choi, J. Baselga, T. J. Lynch, L. W. Ellisen, M. Mino-Kenudson, M. Lanuti, D. R. Borger, A. J. Iafrate, J. A. Engelman, D. Dias-Santagata. (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology 22:12, 2616-2624
CrossRef50
Changcun Guo, Christopher J. Pirozzi, Giselle Y. Lopez, Hai Yan. (2011) Isocitrate dehydrogenase mutations in gliomas. Current Opinion in Neurology 24:6, 648-652
CrossRef51
Jae Kyung Myung, Sun-ju Byeon, Bomi Kim, Jahee Suh, Seung-Ki Kim, Chul-Kee Park, Chun Kee Chung, Kee-Hyun Chang, Sung-Hye Park. (2011) Papillary Glioneuronal Tumors. The American Journal of Surgical Pathology 35:12, 1794-1805
CrossRef52
Janine M. Lupo, Yan Li, Christopher P. Hess, Sarah J. Nelson. (2011) Advances in ultra-high field MRI for the clinical management of patients with brain tumors. Current Opinion in Neurology 24:6, 605-615
CrossRef53
Shigeo Ohba, Kazuhiko Shimizu, Syunsuke Shibao, Tomoru Miwa, Toru Nakagawa, Hikaru Sasaki, Hideki Murakami. (2011) A glioblastoma arising from the attached region where a meningioma had been totally removed. Neuropathology 31:6, 606-611
CrossRef54
Terreia S Jones, Eric C Holland. (2011) Animal models for glioma drug discovery. Expert Opinion on Drug Discovery 6:12, 1271-1283
CrossRef55
Adriana Olar, Aditya Raghunathan, Constance T. Albarracin, Kenneth D. Aldape, Daniel P. Cahill, Suzanne Z. Powell, J. Clay Goodman, Gregory N. Fuller. (2011) Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. Annals of Diagnostic Pathology
CrossRef56
Amy Pruitt. (2011) Uncommon Presentations of Uncommon Conditions. Journal of Neuro-Ophthalmology 31:4, 297-298
CrossRef57
Mee Joo, Sung-Hye Park, Sun Hee Chang, Hanseong Kim, Chan-Young Choi, Chae-Heuck Lee, Byung Hoon Lee, Yoon Joon Hwang. (2011) Cytogenetic and molecular genetic study on glioblastoma arising in granular cell astrocytoma: a case report. Human Pathology
CrossRef58
J. G. Scott, D. Basanta, P. Chinnaiyan, P. Canoll, K. R. Swanson, A. R. A. Anderson. (2011) Production of 2-hydroxyglutarate by isocitrate dehydrogenase 1-mutated gliomas: an evolutionary alternative to the Warburg shift?. Neuro-Oncology 13:12, 1262-1264
CrossRef59
Michael Weller, Roger Stupp. (2011) Clinical trials in neuro-oncology. Current Opinion in Neurology 24:6, 597-598
CrossRef60
Neil P. Jones, Almut Schulze. (2011) Targeting cancer metabolism – aiming at a tumour's sweet-spot. Drug Discovery Today
CrossRef61
A. Woehrer. (2011) The neuropathological spectrum of brain tumours in children and adolescents. memo - Magazine of European Medical Oncology 4:S3, 6-9
CrossRef62
A F Ghiam, R A Cairns, J Thoms, A Dal Pra, O Ahmed, A Meng, T W Mak, R G Bristow. (2011) IDH mutation status in prostate cancer. Oncogene
CrossRef63
T L Lasho, A Tefferi, A Pardanani, C M Finke, S R Fink, A A Caron, P A Decker, R B Jenkins. (2011) Differential distribution of CCDC26 glioma-risk alleles in myeloid malignancies with mutant IDH1 compared with their IDH2R140-mutated or IDH-unmutated counterparts. Leukemia
CrossRef64
You-Xin Zhou, Jun-Xiang Wang, Ming Feng, Chun-Ming Sun, Ting Sun, Gui-Lin Chen, Zi-Wei Du. (2011) Analysis of Isocitrate Dehydrogenase 1 Mutation in 97 Patients with Glioma. Journal of Molecular Neuroscience
CrossRef65
Twinkal C Pansuriya, Ronald van Eijk, Pio d'Adamo, Maayke A J H van Ruler, Marieke L Kuijjer, Jan Oosting, Anne-Marie Cleton-Jansen, Jolieke G van Oosterwijk, Sofie L J Verbeke, Daniëlle Meijer, Tom van Wezel, Karolin H Nord, Luca Sangiorgi, Berkin Toker, Bernadette Liegl-Atzwanger, Mikel San-Julian, Raf Sciot, Nisha Limaye, Lars-Gunnar Kindblom, Soeren Daugaard, Catherine Godfraind, Laurence M Boon, Miikka Vikkula, Kyle C Kurek, Karoly Szuhai, Pim J French, Judith V M G Bovée. (2011) Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nature Genetics 43:12, 1256-1261
CrossRef66
Ji Xiong, Ying Liu, Shu-Guang Chu, Hong Chen, Hai-Xia Chen, Ying Mao, Yin Wang. (2011) Rosette-forming glioneuronal tumor of the septum pellucidum with extension to the supratentorial ventricles: Rare case with genetic analysis. Neuropathologyno-no
CrossRef67
F. M. Iwamoto, A. F. Hottinger, S. Karimi, E. Riedel, J. Dantis, M. Jahdi, K. S. Panageas, A. B. Lassman, L. E. Abrey, M. Fleisher, L. M. DeAngelis, E. C. Holland, A. Hormigo. (2011) Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro-Oncology 13:11, 1244-1251
CrossRef68
Cécile Thirant, Pascale Varlet, Joanna Lipecka, Morgane Le Gall, Cédric Broussard, Philippe Chafey, Jeanne-Marie Studler, Joelle Lacombe, Séverin Lions, Angélique Guillaudeau, Luc Camoin, Catherine Daumas-Duport, Marie-Pierre Junier, Hervé Chneiweiss. (2011) Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1. PROTEOMICS 11:21, 4139-4154
CrossRef69
Emma E. Ramsay, Philip J. Hogg, Pierre J. Dilda. (2011) Mitochondrial Metabolism Inhibitors for Cancer Therapy. Pharmaceutical Research 28:11, 2731-2744
CrossRef70
Keyur P. Patel, Bedia A. Barkoh, Zhao Chen, Deqin Ma, Neelima Reddy, L. Jeffrey Medeiros, Rajyalakshmi Luthra. (2011) Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia. The Journal of Molecular Diagnostics 13:6, 678-686
CrossRef71
Bastian Malzkorn, Marietta Wolter, Markus J. Riemenschneider, Guido Reifenberger. (2011) Unraveling the Glioma Epigenome-From Molecular Mechanisms to Novel Biomarkers and Therapeutic Targets. Brain Pathology 21:6, 619-632
CrossRef72
Virginie Desestret, Pietro Ciccarino, François Ducray, Emmanuelle Crinière, Blandine Boisselier, Marianne Labussière, Marc Polivka, Ahmed Idbaih, Gentian Kaloshi, Andreas Deimling, Khe Hoang-Xuan, Jean-Yves Delattre, Karima Mokhtari, Marc Sanson. (2011) Prognostic stratification of gliomatosis cerebri by IDH1R132H and INA expression. Journal of Neuro-Oncology 105:2, 219-224
CrossRef73
F Damm, F Thol, I Hollink, M Zimmermann, K Reinhardt, M M van den Heuvel-Eibrink, C M Zwaan, V de Haas, U Creutzig, J-H Klusmann, J Krauter, M Heuser, A Ganser, D Reinhardt, C Thiede. (2011) Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML–BFM and DCOG study groups. Leukemia 25:11, 1704-1710
CrossRef74
Gerald Wertheim, Adam Bagg. (2011) Making a Meal of Multiple Mutations in Acute Myeloid Malignancies. The Journal of Molecular Diagnostics 13:6, 605-608
CrossRef75
Nuno Raimundo, Bora E. Baysal, Gerald S. Shadel. (2011) Revisiting the TCA cycle: signaling to tumor formation. Trends in Molecular Medicine 17:11, 641-649
CrossRef76
Chiara Bardella, Patrick J. Pollard, Ian Tomlinson. (2011) SDH mutations in cancer. Biochimica et Biophysica Acta (BBA) - Bioenergetics 1807:11, 1432-1443
CrossRef77
Nader Sanai, Susan Chang, Mitchel S. Berger. (2011) Low-grade gliomas in adults. Journal of Neurosurgery 115:5, 948-965
CrossRef78
Elizabeth Hyjek, James W. Vardiman. (2011) Myelodysplastic/myeloproliferative neoplasms. Seminars in Diagnostic Pathology 28:4, 283-297
CrossRef79
Marta Mellai, Angela Piazzi, Valentina Caldera, Oriana Monzeglio, Paola Cassoni, Guido Valente, Davide Schiffer. (2011) IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. Journal of Neuro-Oncology 105:2, 345-357
CrossRef80
Jing Li, Meihua Wang, Minhee Won, Edward G. Shaw, Christopher Coughlin, Walter J. Curran, Minesh P. Mehta. (2011) Validation and Simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis Classification for Glioblastoma. International Journal of Radiation Oncology*Biology*Physics 81:3, 623-630
CrossRef81
Qi SongTao, Yu Lei, Gui Si, Ding YanQing, Han HuiXia, Zhang XueLin, Wu LanXiao, Yao Fei. (2011) IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Scienceno-no
CrossRef82
Whitney B. Pope, Robert M. Prins, M. Albert Thomas, Rajakumar Nagarajan, Katharine E. Yen, Mark A. Bittinger, Noriko Salamon, Arthur P. Chou, William H. Yong, Horacio Soto, Neil Wilson, Edward Driggers, Hyun G. Jang, Shinsan M. Su, David P. Schenkein, Albert Lai, Timothy F. Cloughesy, Harley I. Kornblum, Hong Wu, Valeria R. Fantin, Linda M. Liau. (2011) Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. Journal of Neuro-Oncology
CrossRef83
Kimberly Ng, Ryan Kim, Santosh Kesari, Bob Carter, Clark C. Chen. (2011) Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. Journal of Neuro-Oncology
CrossRef84
Jiang Lin, Dong-ming Yao, Jun Qian, Qin Chen, Wei Qian, Yun Li, Jing Yang, Cui-zhu Wang, Hai-yan Chai, Zhen Qian, Gao-fei Xiao, Wen-rong Xu. (2011) IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Annals of Hematology
CrossRef85
David A. Reardon, James E. Herndon, Katherine Peters, Annick Desjardins, April Coan, Emil Lou, Ashley Sumrall, Scott Turner, Sith Sathornsumetee, Jeremy N. Rich, Susan Boulton, Eric S. Lipp, Henry S. Friedman, James J. Vredenburgh. (2011) Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. Journal of Neuro-Oncology
CrossRef86
L-M Sturla, P O Zinn, K Ng, M Nitta, D Kozono, C C Chen, E M Kasper. (2011) Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma. British Journal of Cancer 105:8, 1235-1243
CrossRef87
Ichiyo Shibahara, Yukihiko Sonoda, Masayuki Kanamori, Ryuta Saito, Yoji Yamashita, Toshihiro Kumabe, Mika Watanabe, Hiroyoshi Suzuki, Shunsuke Kato, Chikashi Ishioka, Teiji Tominaga. (2011) IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. International Journal of Clinical Oncology
CrossRef88
A. M. Jankowska, H. Makishima, R. V. Tiu, H. Szpurka, Y. Huang, F. Traina, V. Visconte, Y. Sugimoto, C. Prince, C. O'Keefe, E. D. Hsi, A. List, M. A. Sekeres, A. Rao, M. A. McDevitt, J. P. Maciejewski. (2011) Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118:14, 3932-3941
CrossRef89
S. Bluml, A. Panigrahy, M. Laskov, G. Dhall, M. D. Krieger, M. D. Nelson, J. L. Finlay, F. H. Gilles. (2011) Elevated citrate in pediatric astrocytomas with malignant progression. Neuro-Oncology 13:10, 1107-1117
CrossRef90
A. Idbaih. (2011) « OMICS » et biomarqueurs dans les tumeurs gliales. Revue Neurologique 167:10, 691-698
CrossRef91
Amparo Wolf, Sameer Agnihotri, Diana Munoz, Abhijit Guha. (2011) Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiology of Disease 44:1, 84-91
CrossRef92
Brian M Alexander, Minesh P Mehta. (2011) Role of isocitrate dehydrogenase in glioma. Expert Review of Neurotherapeutics 11:10, 1399-1409
CrossRef93
V. Suri, P. Jha, S. Agarwal, P. Pathak, M. C. Sharma, V. Sharma, S. Shukla, K. Somasundaram, A. K. Mahapatra, S. S. Kale, C. Sarkar. (2011) Molecular profile of oligodendrogliomas in young patients. Neuro-Oncology 13:10, 1099-1106
CrossRef94
M. Rossetto, P. Ciccarino, B. Boisselier, M. Labussiere, M. Sanson. (2011) Metabolism of glioma and IDH1/IDH2 mutations. Revue Neurologique 167:10, 699-703
CrossRef95
Daniel Stieber, Siti A Abdul Rahim, Simone P Niclou. (2011) Novel ways to target brain tumour metabolism. Expert Opinion on Therapeutic Targets 15:10, 1227-1239
CrossRef96
Maria Thom, Ahmed Toma, Shu An, Lillian Martinian, George Hadjivassiliou, Bernardo Ratilal, Andrew Dean, Andrew McEvoy, Sanjay M. Sisodiya, Sebastian Brandner. (2011) One Hundred and One Dysembryoplastic Neuroepithelial Tumors. Journal of Neuropathology and Experimental Neurology 70:10, 859-878
CrossRef97
D. Figarella-Branger, A. Maues de Paula, C. Colin, C. Bouvier. (2011) Histomolecular classification of adult diffuse gliomas: The diagnostic value of immunohistochemical markers. Revue Neurologique 167:10, 683-690
CrossRef98
Dinesh Rakheja, Sergej Konoplev, Mu Su, David Wheeler, Donna M. Muzny, Vivian R. Ruvolo, Robert Collins, Nitin J. Karandikar, Michael Andreeff, Leonard Jeffrey Medeiros, Weina Chen. (2011) High incidence of IDH mutations in acute myeloid leukaemia with cuplike nuclei. British Journal of Haematology 155:1, 125-128
CrossRef99
A K Andersson, D W Miller, J A Lynch, A S Lemoff, Z Cai, S B Pounds, I Radtke, B Yan, J D Schuetz, J E Rubnitz, R C Ribeiro, S C Raimondi, J Zhang, C G Mullighan, S A Shurtleff, B A Schulman, J R Downing. (2011) IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia 25:10, 1570-1577
CrossRef100
P S Ward, J R Cross, C Lu, O Weigert, O Abel-Wahab, R L Levine, D M Weinstock, K A Sharp, C B Thompson. (2011) Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production. Oncogene
CrossRef101
Stephen B. Baylin, Peter A. Jones. (2011) A decade of exploring the cancer epigenome — biological and translational implications. Nature Reviews Cancer 11:10, 726-734
CrossRef102
Kit Man Wong, Thomas J. Hudson, John D. McPherson. (2011) Unraveling the Genetics of Cancer: Genome Sequencing and Beyond. Annual Review of Genomics and Human Genetics 12:1, 407-430
CrossRef103
Cory U. Lago, Ho Joong Sung, Wenzhe Ma, Ping-yuan Wang, Paul M. Hwang. (2011) p53, Aerobic Metabolism, and Cancer. Antioxidants & Redox Signaling 15:6, 1739-1748
CrossRef104
T S Jones, E C Holland. (2011) Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. Oncogene
CrossRef105
C. Bettegowda, N. Agrawal, Y. Jiao, M. Sausen, L. D. Wood, R. H. Hruban, F. J. Rodriguez, D. P. Cahill, R. McLendon, G. Riggins, V. E. Velculescu, S. M. Oba-Shinjo, S. K. N. Marie, B. Vogelstein, D. Bigner, H. Yan, N. Papadopoulos, K. W. Kinzler. (2011) Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma. Science 333:6048, 1453-1455
CrossRef106
S Messina, L Frati, C Leonetti, C Zuchegna, E Di Zazzo, A Calogero, A Porcellini. (2011) Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene 30:35, 3813-3820
CrossRef107
Jason T. Huse, Khedoudja Nafa, Neerav Shukla, Edward R. Kastenhuber, Ehud Lavi, Cyrus V. Hedvat, Marc Ladanyi, Marc K. Rosenblum. (2011) High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas. Acta Neuropathologica 122:3, 367-369
CrossRef108
Peng Wang, Mingming Jin, Ruirui Su, Ping Song, Ming Wang, Guoping Zhu. (2011) Enzymatic characterization of isocitrate dehydrogenase from an emerging zoonotic pathogen Streptococcus suis. Biochimie 93:9, 1470-1475
CrossRef109
Luisa Cimmino, Omar Abdel-Wahab, Ross L. Levine, Iannis Aifantis. (2011) TET Family Proteins and Their Role in Stem Cell Differentiation and Transformation. Cell Stem Cell 9:3, 193-204
CrossRef110
Chiara Bardella, Mona El-Bahrawy, Norma Frizzell, Julie Adam, Nicola Ternette, Emine Hatipoglu, Kimberley Howarth, Linda O'Flaherty, Ian Roberts, Gareth Turner, Jennifer Taylor, Konstantinos Giaslakiotis, Valentine M Macaulay, Adrian L Harris, Ashish Chandra, Heli J Lehtonen, Virpi Launonen, Lauri A Aaltonen, Christopher W Pugh, Radu Mihai, David Trudgian, Benedikt Kessler, John W Baynes, Peter J Ratcliffe, Ian P Tomlinson, Patrick J Pollard. (2011) Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. The Journal of Pathology 225:1, 4-11
CrossRef111
Martin Glas, Oliver Bähr, Jörg Felsberg, Katja Rasch, Dorothee Wiewrodt, Martin Schabet, Matthias Simon, Horst Urbach, Joachim P. Steinbach, Johannes Rieger, Rolf Fimmers, Michael Bamberg, Thomas Nägele, Guido Reifenberger, Michael Weller, Ulrich Herrlinger MD, for the Neuro-Oncology Group of the German Cancer Society. (2011) NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Annals of Neurology 70:3, 445-453
CrossRef112
Thomas B. Daniels, Paul D. Brown, Sara J. Felten, Wenting Wu, Jan C. Buckner, Robert M. Arusell, Walter J. Curran, Ross A. Abrams, David Schiff, Edward G. Shaw. (2011) Validation of EORTC Prognostic Factors for Adults With Low-Grade Glioma: A Report Using Intergroup 86-72-51. International Journal of Radiation Oncology*Biology*Physics 81:1, 218-224
CrossRef113
Matthew G. Vander Heiden. (2011) Targeting cancer metabolism: a therapeutic window opens. Nature Reviews Drug Discovery 10:9, 671-684
CrossRef114
V. E. Velculescu, L. A. Diaz. (2011) Understanding the Enemy. Science Translational Medicine 3:98, 98ps37-98ps37
CrossRef115
Nader Sanai, Susan Chang, Mitchel S. Berger. (2011) Low-grade gliomas in adults. Journal of Neurosurgery1-18
CrossRef116
W-C Chou, K-Y Peng, W-C Lei, B-S Ko, W Tsay, C-H Kuo, H-F Tien. (2011) Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission. Leukemia
CrossRef117
Ute Jungwirth, Christian R. Kowol, Bernhard K. Keppler, Christian G. Hartinger, Walter Berger, Petra Heffeter. (2011) Anticancer Activity of Metal Complexes: Involvement of Redox Processes. Antioxidants & Redox Signaling 15:4, 1085-1127
CrossRef118
Manfred Westphal, Katrin Lamszus. (2011) The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nature Reviews Neuroscience 12:9, 495-508
CrossRef119
John Mascarenhas, Nitin Roper, Pratima Chaurasia, Ronald Hoffman. (2011) Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clinical Epigenetics 2:2, 197-212
CrossRef120
Hao Hu, Cao Deng, Tao Yang, Qiang Dong, Ya Chen, Edouard C Nice, Canhua Huang, Yuquan Wei. (2011) Proteomics revisits the cancer metabolome. Expert Review of Proteomics 8:4, 505-533
CrossRef121
Prerana Jha, Vaishali Suri, Vikas Sharma, Geetika Singh, Mehar Chand Sharma, Pankaj Pathak, Kunzang Chosdol, Pankaj Jha, Ashish Suri, Ashok Kumar Mahapatra, Shashank Sharad Kale, Chitra Sarkar. (2011) IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature. Experimental and Molecular Pathology 91:1, 385-393
CrossRef122
Jason T. Huse, Heidi S. Phillips, Cameron W. Brennan. (2011) Molecular subclassification of diffuse gliomas: Seeing order in the chaos. Glia 59:8, 1190-1199
CrossRef123
Paike Jayadeva Bhat, Lalit Darunte, Venkatesh Kareenhalli, Jaswandi Dandekar, Abhay Kumar. (2011) Can metabolic plasticity be a cause for cancer? Warburg–Waddington legacy revisited. Clinical Epigenetics 2:2, 113-122
CrossRef124
Anthony J. Paravati, Dwight E. Heron, Douglas Landsittel, John C. Flickinger, Arlan Mintz, Yi-Fan Chen, M. Saiful Huq. (2011) Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. Journal of Neuro-Oncology 104:1, 339-349
CrossRef125
Matthias Preusser, Adelheid Wöhrer, Susanne Stary, Romana Höftberger, Berthold Streubel, Johannes A. Hainfellner. (2011) Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the IDH1-R132H Mutation in Diffuse Glioma Biopsy Specimens. Journal of Neuropathology and Experimental Neurology 70:8, 715-723
CrossRef126
Michael Weller, Wolfgang Wick, Andreas von Deimling. (2011) Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas. Glia 59:8, 1200-1204
CrossRef127
Brett J. Theeler, Morris D. Groves. (2011) High-Grade Gliomas. Current Treatment Options in Neurology 13:4, 386-399
CrossRef128
A. Watanabe, H. Ogiwara, S. Ehata, A. Mukasa, S. Ishikawa, D. Maeda, K. Ueki, Y. Ino, T. Todo, Y. Yamada, M. Fukayama, N. Saito, K. Miyazono, H. Aburatani. (2011) Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells. Proceedings of the National Academy of Sciences 108:30, 12384-12389
CrossRef129
Ichiyo Shibahara, Yukihiko Sonoda, Masayuki Kanamori, Ryuta Saito, Toshihiro Kumabe, Teiji Tominaga. (2011) New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status. Brain Tumor Pathology 28:3, 203-208
CrossRef130
David A Reardon, James R Perry, Alba A Brandes, Rakesh Jalali, Wolfgang Wick. (2011) Advances in malignant glioma drug discovery. Expert Opinion on Drug Discovery 6:7, 739-753
CrossRef131
M Fernanda Amary, Krisztian Bacsi, Francesca Maggiani, Stephen Damato, Dina Halai, Fitim Berisha, Robin Pollock, Paul O'Donnell, Anita Grigoriadis, Tim Diss, Malihe Eskandarpour, Nadège Presneau, Pancras CW Hogendoorn, Andrew Futreal, Roberto Tirabosco, Adrienne M Flanagan. (2011) IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. The Journal of Pathology 224:3, 334-343
CrossRef132
Karima Mokhtari, François Ducray, Johan M. Kros, Thierry Gorlia, Ahmed Idbaih, Martin Taphoorn, Pieter Wesseling, Khe Hoang-Xuan, Martin Van den Bent, Marc Sanson. (2011) Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer 117:13, 3014-3026
CrossRef133
Katayoon Kasaian, Steven JM Jones. (2011) A new frontier in personalized cancer therapy: mapping molecular changes. Future Oncology 7:7, 873-894
CrossRef134
Masahiro Mizoguchi, Daisuke Kuga, Yanlei Guan, Nobuhiro Hata, Akira Nakamizo, Koji Yoshimoto, Tomio Sasaki. (2011) Loss of heterozygosity analysis in malignant gliomas. Brain Tumor Pathology 28:3, 191-196
CrossRef135
Hiroko Ohgaki, Paul Kleihues. (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathology 28:3, 177-183
CrossRef136
Yuejun Fu, Rui Huang, Yali Zheng, Zhiyun Zhang, Aihua Liang. (2011) Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy. Biochemical and Biophysical Research Communications 410:2, 218-223
CrossRef137
Takao Watanabe, Kazunari Yachi, Takashi Ohta, Takao Fukushima, Atsuo Yoshino, Yoichi Katayama, Yui Shinojima, Tadashi Terui, Hiroki Nagase. (2011) Non-promoter hypermethylation of zygote arrest 1 (ZAR1) in human brain tumors. Brain Tumor Pathology 28:3, 199-202
CrossRef138
Kelly Moran-Crusio, Linsey Reavie, Alan Shih, Omar Abdel-Wahab, Delphine Ndiaye-Lobry, Camille Lobry, Maria E. Figueroa, Aparna Vasanthakumar, Jay Patel, Xinyang Zhao, Fabiana Perna, Suveg Pandey, Jozef Madzo, Chunxiao Song, Qing Dai, Chuan He, Sherif Ibrahim, Miloslav Beran, Jiri Zavadil, Stephen D. Nimer, Ari Melnick, Lucy A. Godley, Iannis Aifantis, Ross L. Levine. (2011) Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. Cancer Cell 20:1, 11-24
CrossRef139
Aaron G Mammoser, David E Blas-Boria, Mark R Gilbert. (2011) Novel clinical trials in neuro-oncology. Clinical Investigation 1:6, 781-794
CrossRef140
Dhyan Chandra, Keshav K. Singh. (2011) Genetic insights into OXPHOS defect and its role in cancer. Biochimica et Biophysica Acta (BBA) - Bioenergetics 1807:6, 620-625
CrossRef141
Zahra Mojtahedi, Akbar Safaei, Zahra Yousefi, Abbas Ghaderi. (2011) Immunoproteomics of HER2-Positive and HER2-Negative Breast Cancer Patients with Positive Lymph Nodes. OMICS: A Journal of Integrative Biology 15:6, 409-418
CrossRef142
Heli J. Lehtonen. (2011) Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Familial Cancer 10:2, 397-411
CrossRef143
Songmi Noh, Eun Ju Park, Junjeong Choi, Sarah Lee, Seon Jung Jang, Se Hoon Kim. (2011) Mutations in isocitrate dehydrogenase isoforms 1 and 2 are rare events in primary central nervous system and non-central nervous system diffuse large B cell lymphoma. Basic and Applied Pathology 4:2, 58-62
CrossRef144
Ralf S. Schmid, Mark Vitucci, C. Ryan Miller. (2011) Genetically engineered mouse models of diffuse gliomas. Brain Research Bulletin
CrossRef145
Jun Zhao, Shuizhong Liu, Hongwei Wang, Xiaomei Zhang, Tiejiang Kang, Zhanyi Li, Hemin Deng, Wu Yue, Shujie Cao. (2011) Mitotic arrest deficient protein MAD2B is overexpressed in human glioma, with depletion enhancing sensitivity to ionizing radiation. Journal of Clinical Neuroscience 18:6, 827-833
CrossRef146
David T. W. Jones, Shani A. Mulholland, Danita M. Pearson, Deborah S. Malley, Samuel W. S. Openshaw, Sally R. Lambert, Lu Liu, L. Magnus Bäcklund, Koichi Ichimura, V. Peter Collins. (2011) Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts. Acta Neuropathologica 121:6, 753-761
CrossRef147
D. Kita, Y. Hayashi, T. Watanabe, A. Korshunov, A. von Deimling, M. Nakada, Y. Kasahara, Y. Zen, J. Hamada, Y. Hayashi. (2011) Scientific correspondence. Neuropathology and Applied Neurobiology 37:4, 423-427
CrossRef148
Cameron Brennan. (2011) Genomic Profiles of Glioma. Current Neurology and Neuroscience Reports 11:3, 291-297
CrossRef149
Felix Sahm, David Capper, Jochen Meyer, Christian Hartmann, Esther Herpel, Mindaugas Andrulis, Gunhild Mechtersheimer, Iver Petersen, Werner Paulus, Andreas von Deimling. (2011) Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. Histopathology 58:7, 1167-1172
CrossRef150
Shipra Agarwal, Mehar Chand Sharma, Chitra Sarkar, Vaishali Suri, Ayushi Jain, Manish Singh Sharma, Pankaj Ailawadhi, Ajay Garg, Supriya Mallick. (2011) Extraventricular neurocytomas: a morphological and histogenetic consideration. A study of six cases. Pathology 43:4, 327-334
CrossRef151
Beth Pietrak, Huizhen Zhao, Hongwei Qi, Chad Quinn, Enoch Gao, Joseph G. Boyer, Nestor Concha, Kristin Brown, Chaya Duraiswami, Richard Wooster, Sharon Sweitzer, Benjamin Schwartz. (2011) A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of αHG. Biochemistry 50:21, 4804-4812
CrossRef152
H. Makishima, A. M. Jankowska, M. A. McDevitt, C. O'Keefe, S. Dujardin, H. Cazzolli, B. Przychodzen, C. Prince, J. Nicoll, H. Siddaiah, M. Shaik, H. Szpurka, E. Hsi, A. Advani, R. Paquette, J. P. Maciejewski. (2011) CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 117:21, e198-e206
CrossRef153
Thomas J. Hudson. (2011) Cancer genome variation in children, adolescents, and young adults. Cancer 117:S10, 2262-2267
CrossRef154
Orestes E. Solis, Rupal I. Mehta, Albert Lai, Rashi I. Mehta, Lama O. Farchoukh, Richard M. Green, Jerry C. Cheng, Sathima Natarajan, Harry V. Vinters, Timothy Cloughesy, William H. Yong. (2011) Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. Journal of Neuro-Oncology 102:3, 477-484
CrossRef155
François Ducray, Ahmed Idbaih, Xiao-Wei Wang, Caroline Cheneau, Marianne Labussiere, Marc Sanson. (2011) Predictive and prognostic factors for gliomas. Expert Review of Anticancer Therapy 11:5, 781-789
CrossRef156
Mrinal M. Patnaik, Terra L. Lasho, Christy M. Finke, Ryan A. Knudson, Rhett P. Ketterling, Dong Chen, James D. Hoyer, Curtis A. Hanson, Ayalew Tefferi. (2011) Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients. American Journal of Hematology 86:5, 393-398
CrossRef157
Judith W.M. Jeuken, Angelique Sijben, Fonnet E. Bleeker, Sandra H.E. Boots-Sprenger, Jos Rijntjes, Johanna M.M. Gijtenbeek, Wolf Mueller, Pieter Wesseling. (2011) The Nature and Timing of Specific Copy Number Changes in the Course of Molecular Progression in Diffuse Gliomas: Further Elucidation of Their Genetic “Life Story”. Brain Pathology 21:3, 308-320
CrossRef158
Kazuya Motomura, Atsushi Natsume, Yugo Kishida, Hiroyuki Higashi, Yutaka Kondo, Yoko Nakasu, Tatsuya Abe, Hiroki Namba, Kenji Wakai, Toshihiko Wakabayashi. (2011) Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter. Cancer 117:8, 1721-1730
CrossRef159
S. Barbus, B. Tews, D. Karra, M. Hahn, B. Radlwimmer, N. Delhomme, C. Hartmann, J. Felsberg, D. Krex, G. Schackert, R. Martinez, G. Reifenberger, P. Lichter. (2011) Differential Retinoic Acid Signaling in Tumors of Long- and Short-term Glioblastoma Survivors. JNCI Journal of the National Cancer Institute 103:7, 598-601
CrossRef160
Hayato Ikota, Sumihito Nobusawa, Yuko Tanaka, Hideaki Yokoo, Yoichi Nakazato. (2011) High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein. Brain Tumor Pathology 28:2, 107-114
CrossRef161
Shingo Takano, Wei Tian, Masahide Matsuda, Tetsuya Yamamoto, Eiichi Ishikawa, Mika Kato Kaneko, Kentaro Yamazaki, Yukinari Kato, Akira Matsumura. (2011) Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathology 28:2, 115-123
CrossRef162
Dinesh Rakheja, Richard L. Boriack, Midori Mitui, Shama Khokhar, Shelby A. Holt, Payal Kapur. (2011) Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate. Tumor Biology 32:2, 325-333
CrossRef163
M. Kelly Nicholas, Rimas V. Lukas, Steven Chmura, Bakhtihar Yamini, Maciej Lesniak, Peter Pytel. (2011) Molecular Heterogeneity in Glioblastoma: Therapeutic Opportunities and Challenges. Seminars in Oncology 38:2, 243-253
CrossRef164
Emily F. Mason, Jeffrey C. Rathmell. (2011) Cell metabolism: An essential link between cell growth and apoptosis. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1813:4, 645-654
CrossRef165
F. Ducray. (2011) Biomarqueurs pronostiques et facteurs prédictifs de la réponse au traitement dans les gliomes de l’adulte. Pratique Neurologique - FMC 2:2, 64-70
CrossRef166
Craig Horbinski, Julia Kofler, Gabrielle Yeaney, Sandra Camelo-Piragua, Sriram Venneti, David N. Louis, Arie Perry, Geoffrey Murdoch, Marina Nikiforova. (2011) Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas. Brain Pathologyno-no
CrossRef167
José L. Sardina, Guillermo López-Ruano, Beatriz Sánchez-Sánchez, Marcial Llanillo, Angel Hernández-Hernández. (2011) Reactive oxygen species: Are they important for haematopoiesis?. Critical Reviews in Oncology/Hematology
CrossRef168
Sang-Kyun Lim, Sheila R. Alcantara Llaguno, Renee M. McKay, Luis F. Parada. (2011) Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Reports 44:3, 158-164
CrossRef169
M. R. Stratton. (2011) Exploring the Genomes of Cancer Cells: Progress and Promise. Science 331:6024, 1553-1558
CrossRef170
Hector Martinez-Valdez, Blanca Ortiz-Quintero. 2011. Confirmation of a Mutation by Multiple Molecular Approaches. , 303-342.
CrossRef171
Giselle Y López, Thomas J Cummings, Darell D Bigner, Roger E McLendon. 2011. Brain Tumours. .
CrossRef172
U. Schlegel. (2011) Aktuelle Prinzipien der Behandlung maligner Gliome. Der Onkologe 17:3, 255-263
CrossRef173
M. Kunz, N. Thon, S. Eigenbrod, C. Hartmann, R. Egensperger, J. Herms, J. Geisler, C. la Fougere, J. Lutz, J. Linn, S. Kreth, A. von Deimling, J. C. Tonn, H. A. Kretzschmar, G. Popperl, F. W. Kreth. (2011) Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncology 13:3, 307-316
CrossRef174
Tatsuhiro Shibata, Akiko Kokubu, Masashi Miyamoto, Yuko Sasajima, Naoya Yamazaki. (2011) Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation. The American Journal of Pathology 178:3, 1395-1402
CrossRef175
Dinesh Rakheja, Midori Mitui, Richard L. Boriack, Ralph J. DeBerardinis. (2011) Isocitrate dehydrogenase 1/2 mutational analyses and 2-hydroxyglutarate measurements in Wilms tumors. Pediatric Blood & Cancer 56:3, 379-383
CrossRef176
Lynda Chin, Jannik N Andersen, P Andrew Futreal. (2011) Cancer genomics: from discovery science to personalized medicine. Nature Medicine 17:3, 297-303
CrossRef177
Ian J Majewski, René Bernards. (2011) Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nature Medicine304-312
CrossRef178
Mika Kato Kaneko, Wei Tian, Shingo Takano, Hiroyuki Suzuki, Yoshihiko Sawa, Yasukazu Hozumi, Kaoru Goto, Kentaro Yamazaki, Chifumi Kitanaka, Yukinari Kato. (2011) Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochemical and Biophysical Research Communications 406:4, 608-613
CrossRef179
Dennis A. Turner, David Cory Adamson. (2011) Neuronal-Astrocyte Metabolic Interactions. Journal of Neuropathology and Experimental Neurology 70:3, 167-176
CrossRef180
John R Prensner, Arul M Chinnaiyan. (2011) Metabolism unhinged: IDH mutations in cancer. Nature Medicine 17:3, 291-293
CrossRef181
Omar Abdel-Wahab. (2011) Genetics of the myeloproliferative neoplasms. Current Opinion in Hematology 18:2, 117-123
CrossRef182
Ghazaleh Tabatabai, Michael Weller. (2011) Glioblastoma stem cells. Cell and Tissue Research 343:3, 459-465
CrossRef183
Christian Frezza, Patrick J Pollard, Eyal Gottlieb. (2011) Inborn and acquired metabolic defects in cancer. Journal of Molecular Medicine 89:3, 213-220
CrossRef184
Linda B. C. Bralten, Nanne K. Kloosterhof, Rutger Balvers, Andrea Sacchetti, Lariesa Lapre, Martine Lamfers, Sieger Leenstra, Hugo de Jonge, Johan M. Kros, Erwin E. W. Jansen, Eduard A. Struys, Cornelis Jakobs, Gajja S. Salomons, Sander H. Diks, Maikel Peppelenbosch, Andreas Kremer, Casper C. Hoogenraad, Peter A. E. Sillevis Smitt, Pim J. French. (2011) IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Annals of Neurology 69:3, 455-463
CrossRef185
Alison Farrell. (2011) A close look at cancer. Nature Medicine 17:3, 262-265
CrossRef186
Grischa Toedt, Sebastian Barbus, Marietta Wolter, Jörg Felsberg, Björn Tews, Frederic Blond, Michael C. Sabel, Stefanie Hofmann, Natalia Becker, Christian Hartmann, Hiroko Ohgaki, Andreas von Deimling, Otmar D. Wiestler, Meinhard Hahn, Peter Lichter, Guido Reifenberger, Bernhard Radlwimmer. (2011) Molecular signatures classify astrocytic gliomas by IDH1 mutation status. International Journal of Cancer 128:5, 1095-1103
CrossRef187
V K Hill, N Underhill-Day, D Krex, K Robel, C B Sangan, H R Summersgill, M Morris, D Gentle, A D Chalmers, E R Maher, F Latif. (2011) Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 30:8, 978-989
CrossRef188
Z. J. Reitman, G. Jin, E. D. Karoly, I. Spasojevic, J. Yang, K. W. Kinzler, Y. He, D. D. Bigner, B. Vogelstein, H. Yan. (2011) Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proceedings of the National Academy of Sciences 108:8, 3270-3275
CrossRef189
Bredel, Markus, Scholtens, Denise M., Yadav, Ajay K., Alvarez, Angel A., Renfrow, Jaclyn J., Chandler, James P., Yu, Irene L.Y., Carro, Maria S., Dai, Fangping, Tagge, Michael J., Ferrarese, Roberto, Bredel, Claudia, Phillips, Heidi S., Lukac, Paul J., Robe, Pierre A., Weyerbrock, Astrid, Vogel, Hannes, Dubner, Steven, Mobley, Bret, He, Xiaolin, Scheck, Adrienne C., Sikic, Branimir I., Aldape, Kenneth D., Chakravarti, Arnab, Harsh, Griffith R. IV, . (2011) NFKBIA Deletion in Glioblastomas. New England Journal of Medicine 364:7, 627-637
Full Text190
M Vitucci, D N Hayes, C R Miller. (2011) Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. British Journal of Cancer 104:4, 545-553
CrossRef191
A. Wolf, S. Agnihotri, J. Micallef, J. Mukherjee, N. Sabha, R. Cairns, C. Hawkins, A. Guha. (2011) Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. Journal of Experimental Medicine 208:2, 313-326
CrossRef192
Eric D. Green, Mark S. Guyer, Eric D. Green, Mark S. Guyer, Teri A. Manolio, Jane L. Peterson. (2011) Charting a course for genomic medicine from base pairs to bedside. Nature 470:7333, 204-213
CrossRef193
L. V. O'Keefe, A. Colella, S. Dayan, Q. Chen, A. Choo, R. Jacob, G. Price, D. Venter, R. I. Richards. (2011) Drosophila orthologue of WWOX, the chromosomal fragile site FRA16D tumour suppressor gene, functions in aerobic metabolism and regulates reactive oxygen species. Human Molecular Genetics 20:3, 497-509
CrossRef194
Stephen H. Settle, Erik P. Sulman. (2011) Tumor Profiling: Development of Prognostic and Predictive Factors to Guide Brain Tumor Treatment. Current Oncology Reports 13:1, 26-36
CrossRef195
Thomas Robertson, Barbara Koszyca, Michael Gonzales. (2011) Overview and recent advances in neuropathology. Part 1: Central nervous system tumours. Pathology 43:2, 88-92
CrossRef196
David Basanta, Jacob G Scott, Russ Rockne, Kristin R Swanson, Alexander R A Anderson. (2011) The role of IDH1 mutated tumour cells in secondary glioblastomas: an evolutionary game theoretical view. Physical Biology 8:1, 015016
CrossRef197
Rob A. Cairns, Isaac S. Harris, Tak W. Mak. (2011) Regulation of cancer cell metabolism. Nature Reviews Cancer 11:2, 85-95
CrossRef198
Susan C. Williams, Matthias A. Karajannis, Luis Chiriboga, John G. Golfinos, Andreas Deimling, David Zagzag. (2011) R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1α upregulation in adult glioma. Acta Neuropathologica 121:2, 279-281
CrossRef199
T. Suzuki, M. Nakada, Y. Yoshida, E. Nambu, N. Furuyama, D. Kita, Y. Hayashi, Y. Hayashi, J.-i. Hamada. (2011) The Correlation between Promoter Methylation Status and the Expression Level of O6-Methylguanine-DNA Methyltransferase in Recurrent Glioma. Japanese Journal of Clinical Oncology 41:2, 190-196
CrossRef200
Sandra Camelo-Piragua, Michael Jansen, Aniruddha Ganguly, James ChulMin Kim, Arjola K. Cosper, Dora Dias-Santagata, Catherine L. Nutt, A. John Iafrate, David N. Louis. (2011) A Sensitive and Specific Diagnostic Panel to Distinguish Diffuse Astrocytoma From Astrocytosis. Journal of Neuropathology and Experimental Neurology 70:2, 110-115
CrossRef201
David Capper, David Reuss, Jens Schittenhelm, Christian Hartmann, Juliane Bremer, Felix Sahm, Patrick N. Harter, Astrid Jeibmann, Andreas Deimling. (2011) Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathologica 121:2, 241-252
CrossRef202
W. Taal, H. J. Dubbink, C. B. L. Zonnenberg, B. A. Zonnenberg, T. J. Postma, J. M. M. Gijtenbeek, W. Boogerd, F. H. Groenendijk, J. M. Kros, M. C. M. Kouwenhoven, R. van Marion, I. van Heuvel, B. van der Holt, J. E. C. Bromberg, P. A. E. Sillevis Smitt, W. N. M. Dinjens, M. J. van den Bent, . (2011) First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro-Oncology 13:2, 235-241
CrossRef203
Michael P. Lisanti. (2011) Caveolin-Related Diseases. Annual Review of Pathology: Mechanisms of Disease 7:1, 110301101326014
CrossRef204
B. C. Christensen, A. A. Smith, S. Zheng, D. C. Koestler, E. A. Houseman, C. J. Marsit, J. L. Wiemels, H. H. Nelson, M. R. Karagas, M. R. Wrensch, K. T. Kelsey, J. K. Wiencke. (2011) DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma. JNCI Journal of the National Cancer Institute 103:2, 143-153
CrossRef205
Robert Dubrow, Amy S Darefsky. (2011) Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007. BMC Cancer 11:1, 325
CrossRef206
Gang Bao, Maode Wang, Shiwen Guo, Yuliang Han, Gaofeng Xu. (2011) Vascular Endothelial Growth Factor +936 C/T Gene Polymorphism and Glioma Risk in a Chinese Han Population. Genetic Testing and Molecular Biomarkers 15:1-2, 103-106
CrossRef207
Mathieu Cloutier, Edwin Wang. (2011) Dynamic modeling and analysis of cancer cellular network motifs. Integrative Biology 3:7, 724
CrossRef208
Erik P. Sulman, Ken Aldape. (2011) The Use of Global Profiling in Biomarker Development for Gliomas. Brain Pathology 21:1, 88-95
CrossRef209
Federica Sotgia, Ubaldo E Martinez-Outschoorn, Stephanos Pavlides, Anthony Howell, Richard G Pestell, Michael P Lisanti. (2011) Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Research 13:4, 213
CrossRef210
Maximilian Niyazi, Franz Zehentmayr, Olivier M Niemöller, Sabina Eigenbrod, Hans Kretzschmar, Klaus-Schulze Osthoff, Jörg-Christian Tonn, Mike Atkinson, Simone Mörtl, Claus Belka. (2011) MiRNA expression patterns predict survival in glioblastoma. Radiation Oncology 6:1, 153
CrossRef211
Avadhut D Joshi, D Parsons, Victor E Velculescu, Gregory J Riggins. (2011) Sodium ion channel mutations in glioblastoma patients correlate with shorter survival. Molecular Cancer 10:1, 17
CrossRef212
K Yoshida, M Sanada, M Kato, R Kawahata, A Matsubara, J Takita, L-Y Shih, H Mori, H P Koeffler, S Ogawa. (2011) A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. Leukemia 25:1, 184-186
CrossRef213
Anke Waha, Jörg Felsberg, Wolfgang Hartmann, Jennifer Hammes, Anna von dem Knesebeck, Elmar Endl, Torsten Pietsch, Andreas Waha. (2011) Frequent epigenetic inactivation of the chaperone SGNE1/7B2 in human gliomas. International Journal of Cancern/a-n/a
CrossRef214
S Soverini, J Score, I Iacobucci, A Poerio, A Lonetti, A Gnani, S Colarossi, A Ferrari, F Castagnetti, G Rosti, F Cervantes, A Hochhaus, M Delledonne, A Ferrarini, M Sazzini, D Luiselli, M Baccarani, N C P Cross, G Martinelli. (2011) IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. Leukemia 25:1, 178-181
CrossRef215
Stephanie E Combs, Stefan Rieken, Wolfgang Wick, Amir Abdollahi, Andreas von Deimling, Jürgen Debus, Christian Hartmann. (2011) Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?. Radiation Oncology 6:1, 115
CrossRef216
Ramiro Mendoza-Maldonado, Valentina Faoro, Sailesh Bajpai, Matteo Berti, Federico Odreman, Marco Vindigni, Tamara Ius, Abdollah Ghasemian, Serena Bonin, Miran Skrap, Giorgio Stanta, Alessandro Vindigni. (2011) The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation. Molecular Cancer 10:1, 83
CrossRef217
Wei Yan, Wei Zhang, Tao Jiang. (2011) Oncogene addiction in gliomas: Implications for molecular targeted therapy. Journal of Experimental & Clinical Cancer Research 30:1, 58
CrossRef218
, Ian F. Pollack, Ronald L. Hamilton, Robert W. Sobol, Marina N. Nikiforova, Maureen A. Lyons-Weiler, William A. LaFramboise, Peter C. Burger, Daniel J. Brat, Marc K. Rosenblum, Emiko J. Holmes, Tianni Zhou, Regina I. Jakacki. (2011) IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group. Child's Nervous System 27:1, 87-94
CrossRef219
Remco J. Molenaar. (2011) Ion Channels in Glioblastoma. ISRN Neurology 2011, 1-7
CrossRef220
Ichiyo SHIBAHARA, Tomohiro KAWAGUCHI, Masayuki KANAMORI, Shingo YONEZAWA, Hiroki TAKAZAWA, Kenichiro ASANO, Hiroki OHKUMA, Mitsuomi KAIMORI, Tatsuya SASAKI, Michiharu NISHIJIMA. (2011) Pilocytic Astrocytoma With Histological Malignant Features Without Previous Radiation Therapy. Neurologia medico-chirurgica 51:2, 144-147
CrossRef221
Nanne K Kloosterhof, Linda BC Bralten, Hendrikus J Dubbink, Pim J French, Martin J van den Bent. (2011) Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. The Lancet Oncology 12:1, 83-91
CrossRef222
Andreas Von Deimling, Andrey Korshunov, Christian Hartmann. (2011) The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. Brain Pathology 21:1, 74-87
CrossRef223
Tomoru Miwa, Yuichi Hirose, Hikaru Sasaki, Taketo Ezaki, Kazunari Yoshida, Takeshi Kawase. (2011) Single-Copy Gain of Chromosome 1q Is a Negative Prognostic Marker in Pediatric Nonependymal, Nonpilocytic Gliomas. Neurosurgery 68:1, 206-212
CrossRef224
Timothy A. Graubert, Elaine R. Mardis. (2011) Genomics of Acute Myeloid Leukemia. The Cancer Journal 17:6, 487-491
CrossRef225
Farhad Ravandi, Keyur Patel, Rajyalakshmi Luthra, Stefan Faderl, Marina Konopleva, Tapan Kadia, Mark Brandt, Sherry Pierce, Steven Kornblau, Michael Andreeff, Xuemei Wang, Guillermo Garcia-Manero, Jorge Cortes, Hagop Kantarjian. (2011) Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancern/a-n/a
CrossRef226
Vlad C. Sandulache, Heath D. Skinner, Thomas J. Ow, Aijun Zhang, Xuefeng Xia, James M. Luchak, Lee-Jun C. Wong, Curtis R. Pickering, Ge Zhou, Jeffrey N. Myers. (2011) Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancern/a-n/a
CrossRef227
S. Schnittger, C. Haferlach, M. Ulke, T. Alpermann, W. Kern, T. Haferlach. (2010) IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 116:25, 5486-5496
CrossRef228
K E Yen, M A Bittinger, S M Su, V R Fantin. (2010) Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29:49, 6409-6417
CrossRef229
S. L. McKnight. (2010) On Getting There from Here. Science 330:6009, 1338-1339
CrossRef230
Maria E. Figueroa, Omar Abdel-Wahab, Chao Lu, Patrick S. Ward, Jay Patel, Alan Shih, Yushan Li, Neha Bhagwat, Aparna Vasanthakumar, Hugo F. Fernandez, Martin S. Tallman, Zhuoxin Sun, Kristy Wolniak, Justine K. Peeters, Wei Liu, Sung E. Choe, Valeria R. Fantin, Elisabeth Paietta, Bob Löwenberg, Jonathan D. Licht, Lucy A. Godley, Ruud Delwel, Peter J.M. Valk, Craig B. Thompson, Ross L. Levine, Ari Melnick. (2010) Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell 18:6, 553-567
CrossRef231
Ruth G. Tatevossian, Bo Tang, James Dalton, Tim Forshew, Andrew R. Lawson, Jing Ma, Geoff Neale, Sheila A. Shurtleff, Simon Bailey, Amar Gajjar, Suzanne J. Baker, Denise Sheer, David W. Ellison. (2010) MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathologica 120:6, 731-743
CrossRef232
Ryan T. Merrell, S. Keith Anderson, Fredric B. Meyer, Daniel H. Lachance. (2010) Seizures in patients with glioma treated with phenytoin and levetiracetam. Journal of Neurosurgery 113:6, 1176-1181
CrossRef233
Christian Hartmann, Bettina Hentschel, Wolfgang Wick, David Capper, Jörg Felsberg, Matthias Simon, Manfred Westphal, Gabriele Schackert, Richard Meyermann, Torsten Pietsch, Guido Reifenberger, Michael Weller, Markus Loeffler, Andreas Deimling. (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica 120:6, 707-718
CrossRef234
Philippe Metellus, Bema Coulibaly, Carole Colin, Andre Maues Paula, Alexandre Vasiljevic, David Taieb, Anne Barlier, Blandine Boisselier, Karima Mokhtari, Xiao Wei Wang, Anderson Loundou, Frederique Chapon, Sandrine Pineau, L’Houcine Ouafik, Olivier Chinot, Dominique Figarella-Branger. (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathologica 120:6, 719-729
CrossRef235
Judith WM Jeuken, Pieter Wesseling. (2010) MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potential. The Journal of Pathology 222:4, 324-328
CrossRef236
Blandine Boisselier, Yannick Marie, Marianne Labussière, Pietro Ciccarino, Virginie Desestret, XiaoWei Wang, Laurent Capelle, Jean-Yves Delattre, Marc Sanson. (2010) COLD PCR HRM: a highly sensitive detection method for IDH1 mutations. Human Mutation 31:12, 1360-1365
CrossRef237
Elizabeth A. Eklund, Pradip Raychaudhuri, Leonidas C. Platanias. (2010) Correlation between IDH2 mutations and disease status in acute myeloid leukemia. Leukemia & Lymphoma 51:12, 2157-2158
CrossRef238
Judith Favier, Anne-Paule Gimenez-Roqueplo. (2010) Pheochromocytomas: The (pseudo)-hypoxia hypothesis. Best Practice & Research Clinical Endocrinology & Metabolism 24:6, 957-968
CrossRef239
Langmei Deng, Tao Su, Aimin Leng, Xiaomei Zhang, Meihua xu, Lu Yan, Huan Gu, Guiying Zhang. (2010) Upregulation of soluble resistance-related calcium-binding protein (sorcin) in gastric cancer. Medical Oncology 27:4, 1102-1108
CrossRef240
Alba A. Brandes, Enrico Franceschi. (2010) Neuro-oncology: Genetic variation in pediatric and adult brain tumors. Nature Reviews Neurology 6:12, 653-654
CrossRef241
Young-Ho Kim, Sumihito Nobusawa, Michel Mittelbronn, Werner Paulus, Benjamin Brokinkel, Kathy Keyvani, Ulrich Sure, Karsten Wrede, Yoichi Nakazato, Yuko Tanaka, Anne Vital, Luigi Mariani, Robert Stawski, Takuya Watanabe, Umberto De Girolami, Paul Kleihues, Hiroko Ohgaki. (2010) Molecular Classification of Low-Grade Diffuse Gliomas. The American Journal of Pathology 177:6, 2708-2714
CrossRef242
Takanori Hirose, Keisuke Ishizawa, Shio Shimada. (2010) Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors. Neuropathology 30:6, 586-596
CrossRef243
T. David Bourne, David Schiff. (2010) Update on molecular findings, management and outcome in low-grade gliomas. Nature Reviews Neurology 6:12, 695-701
CrossRef244
Ivana Jeziskova, Filip Razga, Monika Bajerova, Zdenek Racil, Jiri Mayer, Dana Dvorakova. (2010) IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status. Leukemia & Lymphoma 51:12, 2285-2287
CrossRef245
Shimin Zhao, Kun-Liang Guan. (2010) IDH1 mutant structures reveal a mechanism of dominant inhibition. Cell Research 20:12, 1279-1281
CrossRef246
Lee F. Starker, Alberto Delgado-Verdugo, Robert Udelsman, Peyman Björklund, Tobias Carling. (2010) Expression and somatic mutations of SDHAF2 (SDH5), a novel endocrine tumor suppressor gene in parathyroid tumors of primary hyperparathyroidism. Endocrine 38:3, 397-401
CrossRef247
L B C Bralten, A M Gravendeel, N K Kloosterhof, A Sacchetti, T Vrijenhoek, J A Veltman, M J van den Bent, J M Kros, C C Hoogenraad, P A E Sillevis Smitt, P J French. (2010) The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma. Oncogene 29:46, 6138-6148
CrossRef248
Matthias Preusser, Sabina Plumer, Elisabeth Dirnberger, Johannes A. Hainfellner, Christine Mannhalter. (2010) Fixation of Brain Tumor Biopsy Specimens with RCL2 Results in Well-Preserved Histomorphology, Immunohistochemistry and Nucleic Acids. Brain Pathology 20:6, 1010-1020
CrossRef249
Ad Geurts van Kessel. (2010) The ‘omics’ of cancer. Cancer Genetics and Cytogenetics 203:1, 37-42
CrossRef250
Yang Zou, Yun Zeng, Deng-Feng Zhang, Shan-Hua Zou, Yun-Feng Cheng, Yong-Gang Yao. (2010) IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochemical and Biophysical Research Communications 402:2, 378-383
CrossRef251
Prashanth Setty, Jennifer Hammes, Thomas Rothämel, Valentina Vladimirova, Christof M. Kramm, Torsten Pietsch, Andreas Waha. (2010) A Pyrosequencing-Based Assay for the Rapid Detection of IDH1 Mutations in Clinical Samples. The Journal of Molecular Diagnostics 12:6, 750-756
CrossRef252
Michael D. Jenkinson, Carol Walker, Andrew R. Brodbelt, Simone Wilkins, David Husband, Brian Haylock. (2010) Molecular genetics, imaging and treatment of oligodendroglial tumours. Acta Neurochirurgica 152:11, 1815-1825
CrossRef253
Bei Yang, Chen Zhong, Yingjie Peng, Zheng Lai, Jianping Ding. (2010) Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H. Cell Research 20:11, 1188-1200
CrossRef254
Markus J. Riemenschneider, Judith W. M. Jeuken, Pieter Wesseling, Guido Reifenberger. (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathologica 120:5, 567-584
CrossRef255
N. Bhagwat, R. L. Levine. (2010) Metabolic Syndromes and Malignant Transformation: Where the Twain Shall Meet. Science Translational Medicine 2:54, 54ps50-54ps50
CrossRef256
M. Kranendijk, E. A. Struys, E. van Schaftingen, K. M. Gibson, W. A. Kanhai, M. S. van der Knaap, J. Amiel, N. R. Buist, A. M. Das, J. B. de Klerk, A. S. Feigenbaum, D. K. Grange, F. C. Hofstede, E. Holme, E. P. Kirk, S. H. Korman, E. Morava, A. Morris, J. Smeitink, R. N. Sukhai, H. Vallance, C. Jakobs, G. S. Salomons. (2010) IDH2 Mutations in Patients with D-2-Hydroxyglutaric Aciduria. Science 330:6002, 336-336
CrossRef257
C. L. Green, C. M. Evans, R. K. Hills, A. K. Burnett, D. C. Linch, R. E. Gale. (2010) The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116:15, 2779-2782
CrossRef258
Peter Dromparis, Gopinath Sutendra, Evangelos D. Michelakis. (2010) The role of mitochondria in pulmonary vascular remodeling. Journal of Molecular Medicine 88:10, 1003-1010
CrossRef259
Maura Massimino, Filippo Spreafico, Daria Riva, Veronica Biassoni, Geraldina Poggi, Carlo Solero, Lorenza Gandola, Lorenzo Genitori, Piergiorgio Modena, Fabio Simonetti, Paolo Potepan, Michela Casanova, Cristina Meazza, Carlo A. Clerici, Serena Catania, Iacopo Sardi, Felice Giangaspero. (2010) A lower-dose, lower-toxicity cisplatin–etoposide regimen for childhood progressive low-grade glioma. Journal of Neuro-Oncology 100:1, 65-71
CrossRef260
William G. Kaelin Jr.. (2010) New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. Annals of the New York Academy of Sciences 1210:1, 1-7
CrossRef261
S. Abbas, S. Lugthart, F. G. Kavelaars, A. Schelen, J. E. Koenders, A. Zeilemaker, W. J. L. van Putten, A. W. Rijneveld, B. Lowenberg, P. J. M. Valk. (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 116:12, 2122-2126
CrossRef262
Ines Batinić-Haberle, Júlio S. Rebouças, Ivan Spasojević. (2010) Superoxide Dismutase Mimics: Chemistry, Pharmacology, and Therapeutic Potential. Antioxidants & Redox Signaling 13:6, 877-918
CrossRef263
Lenny Dang, Shengfang Jin, Shinsan M. Su. (2010) IDH mutations in glioma and acute myeloid leukemia. Trends in Molecular Medicine 16:9, 387-397
CrossRef264
Silvia Hofer, Andrew B. Lassman. (2010) Molecular markers in gliomas: impact for the clinician. Targeted Oncology 5:3, 201-210
CrossRef265
Sarah E. Calvo, Vamsi K. Mootha. (2010) The Mitochondrial Proteome and Human Disease. Annual Review of Genomics and Human Genetics 11:1, 25-44
CrossRef266
Lindsay B. Robertson, Georgina N. Armstrong, Bianca D. Olver, Amy L. Lloyd, Sanjay Shete, Ching Lau, Elizabeth B. Claus, Jill Barnholtz-Sloan, Rose Lai, Dora Il’yasova, Joellen Schildkraut, Jonine L. Bernstein, Sara H. Olson, Robert B. Jenkins, Ping Yang, Amanda L. Rynerason, Margaret Wrensch, Lucie McCoy, John K. Wienkce, Bridget McCarthy, Faith Davis, Nicholas A. Vick, Christoffer Johansen, Hanne Bødtcher, Siegal Sadetzki, Revital Bar-Sade Bruchim, Galit Hirsh Yechezkel, Ulrika Andersson, Beatrice S. Melin, Melissa L. Bondy, Richard S. Houlston. (2010) Survey of familial glioma and role of germline p16 INK4A /p14 ARF and p53 mutation. Familial Cancer 9:3, 413-421
CrossRef267
Manila Antonelli, Francesca Romana Buttarelli, Antonietta Arcella, Sumihito Nobusawa, Vittoria Donofrio, Hiroko Oghaki, Felice Giangaspero. (2010) Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. Journal of Neuro-Oncology 99:2, 209-215
CrossRef268
Michael W. Ronellenfitsch, Joachim P. Steinbach, Wolfgang Wick. (2010) Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives. Targeted Oncology 5:3, 183-191
CrossRef269
Michael Weller, Wolfgang Wick, Monika E Hegi, Roger Stupp, Ghazaleh Tabatabai. (2010) Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. Future Oncology 6:9, 1407-1414
CrossRef270
Robert E. Rogers, Ralph J. DeBerardinis, Laura J. Klesse, Richard L. Boriack, Linda R. Margraf, Dinesh Rakheja. (2010) Wilms Tumor in a Child with L-2-hydroxyglutaric Aciduria. Pediatric and Developmental Pathology 13:5, 408-411
CrossRef271
Marie Zbinden, Arnaud Duquet, Aiala Lorente-Trigos, Sandra-Nadia Ngwabyt, Isabel Borges, Ariel Ruiz i Altaba. (2010) NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. The EMBO Journal 29:15, 2659-2674
CrossRef272
Ingeborg Fischer, Kenneth Aldape. (2010) Molecular Tools: Biology, Prognosis, and Therapeutic Triage. Neuroimaging Clinics of North America 20:3, 273-282
CrossRef273
Marcel Seiz, Jochen Tuettenberg, Jochen Meyer, Marco Essig, Kirsten Schmieder, Christian Mawrin, Andreas Deimling, Christian Hartmann. (2010) Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathologica 120:2, 261-267
CrossRef274
Eudocia C. Quant, Patrick Y. Wen. (2010) Novel Medical Therapeutics in Glioblastomas, Including Targeted Molecular Therapies, Current and Future Clinical Trials. Neuroimaging Clinics of North America 20:3, 425-448
CrossRef275
W. Wick, M. Weller. (2010) Anaplastische Gliome. Der Nervenarzt 81:8, 928-935
CrossRef276
ShengTao Zhou, CanHua Huang, YuQuan Wei. (2010) The metabolic switch and its regulation in cancer cells. Science China Life Sciences 53:8, 942-958
CrossRef277
F. Thol, F. Damm, K. Wagner, G. Gohring, B. Schlegelberger, D. Hoelzer, M. Lubbert, W. Heit, L. Kanz, G. Schlimok, A. Raghavachar, W. Fiedler, H. Kirchner, G. Heil, M. Heuser, J. Krauter, A. Ganser. (2010) Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 116:4, 614-616
CrossRef278
W.-C. Chou, Y.-N. Huang, C.-F. Huang, M.-H. Tseng, H.-F. Tien. (2010) A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations. Blood 116:3, 495-496
CrossRef279
Z. J. Reitman, H. Yan. (2010) Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism. JNCI Journal of the National Cancer Institute 102:13, 932-941
CrossRef280
Andreana L Rivera, Christopher E Pelloski. (2010) Diagnostic and prognostic molecular markers in common adult gliomas. Expert Review of Molecular Diagnostics 10:5, 637-649
CrossRef281
Pierre Giglio, John Lee Villano. (2010) Newly Diagnosed High-Grade Gliomas. Current Treatment Options in Neurology 12:4, 309-320
CrossRef282
Craig Horbinski, Lindsey Kelly, Yuri E. Nikiforov, Mary Beth Durso, Marina N. Nikiforova. (2010) Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies. The Journal of Molecular Diagnostics 12:4, 487-492
CrossRef283
J. J. P. Kelly, M. D. Blough, O. D. M. Stechishin, J. A. W. Chan, D. Beauchamp, M. Perizzolo, D. J. Demetrick, L. Steele, R. N. Auer, W. J. Hader, M. Westgate, I. F. Parney, R. Jenkins, J. G. Cairncross, S. Weiss. (2010) Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro-Oncology 12:7, 745-755
CrossRef284
Michael Jansen, Stephen Yip, David N Louis. (2010) Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. The Lancet Neurology 9:7, 717-726
CrossRef285
A Tefferi, T L Lasho, O Abdel-Wahab, P Guglielmelli, J Patel, D Caramazza, L Pieri, C M Finke, O Kilpivaara, M Wadleigh, M Mai, R F McClure, D G Gilliland, R L Levine, A Pardanani, A M Vannucchi. (2010) IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 24:7, 1302-1309
CrossRef286
M. J. Dougherty, M. Santi, M. S. Brose, C. Ma, A. C. Resnick, A. J. Sievert, P. B. Storm, J. A. Biegel. (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro-Oncology 12:7, 621-630
CrossRef287
Zachary J. Reitman, Natasha J. Olby, Christopher L. Mariani, Rachael Thomas, Matthew Breen, Darell D. Bigner, Roger E. McLendon, Hai Yan. (2010) IDH1 and IDH2 hotspot mutations are not found in canine glioma. International Journal of Cancer 127:1, 245-246
CrossRef288
Ramon Martinez, Manel Esteller. (2010) The DNA methylome of glioblastoma multiforme. Neurobiology of Disease 39:1, 40-46
CrossRef289
Giselle Y. Lopez, Zachary J. Reitman, David Solomon, Todd Waldman, Darell D. Bigner, Roger E. McLendon, Steven A Rosenberg, Yardena Samuels, Hai Yan. (2010) IDH1R132 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochemical and Biophysical Research Communications 398:3, 585-587
CrossRef290
G. Benard, N. Bellance, C. Jose, S. Melser, K. Nouette-Gaulain, R. Rossignol. (2010) Multi-site control and regulation of mitochondrial energy production. Biochimica et Biophysica Acta (BBA) - Bioenergetics 1797:6-7, 698-709
CrossRef291
A Pardanani, T L Lasho, C M Finke, M Mai, R F McClure, A Tefferi. (2010) IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 24:6, 1146-1151
CrossRef292
Min Sung Kim, Soo Young Hur, Nam Jin Yoo, Sug Hyung Lee. (2010) Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. The Journal of Pathology 221:2, 147-152
CrossRef293
Yuejun Fu, Rui Huang, Jun Du, Renjia Yang, Na An, Aihua Liang. (2010) Glioma-derived mutations in IDH: From mechanism to potential therapy. Biochemical and Biophysical Research Communications 397:2, 127-130
CrossRef294
C. Rory Goodwin, John Laterra. (2010) Neuro-oncology: Unmasking the multiforme in glioblastoma. Nature Reviews Neurology 6:6, 304-305
CrossRef295
Jean-Pierre Bayley, Peter Devilee. (2010) Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?. Current Opinion in Genetics & Development 20:3, 324-329
CrossRef296
A Tefferi. (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24:6, 1128-1138
CrossRef297
Richard Wooster, Kurtis E Bachman. (2010) Catalogue, cause, complexity and cure; the many uses of cancer genome sequence. Current Opinion in Genetics & Development 20:3, 336-341
CrossRef298
E. D. Michelakis, G. Sutendra, P. Dromparis, L. Webster, A. Haromy, E. Niven, C. Maguire, T. L. Gammer, J. R. Mackey, D. Fulton, B. Abdulkarim, M. S. McMurtry, K. C. Petruk. (2010) Metabolic Modulation of Glioblastoma with Dichloroacetate. Science Translational Medicine 2:31, 31ra34-31ra34
CrossRef299
Craig Horbinski. (2010) Practical molecular diagnostics in neuropathology: making a tough job a little easier. Seminars in Diagnostic Pathology 27:2, 105-113
CrossRef300
O Kosmider, V Gelsi-Boyer, L Slama, F Dreyfus, O Beyne-Rauzy, B Quesnel, M Hunault-Berger, B Slama, N Vey, C Lacombe, E Solary, D Birnbaum, O A Bernard, M Fontenay. (2010) Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 24:5, 1094-1096
CrossRef301
R. Stupp, J.- C. Tonn, M. Brada, G. Pentheroudakis, . (2010) High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v190-v193
CrossRef302
Karen D. Wright, Richard J. Gilbertson. (2010) To Infinium, and Beyond!. Cancer Cell 17:5, 419-420
CrossRef303
Marianne Labussiere, Xiao-Wei Wang, Ahmed Idbaih, François Ducray, Marc Sanson. (2010) Prognostic markers in gliomas. Future Oncology 6:5, 733-739
CrossRef304
P A Ho, T A Alonzo, K J Kopecky, K L Miller, J Kuhn, R Zeng, R B Gerbing, S C Raimondi, B A Hirsch, V Oehler, C A Hurwitz, J L Franklin, A S Gamis, S H Petersdorf, J E Anderson, G H Reaman, L H Baker, C L Willman, I D Bernstein, J P Radich, F R Appelbaum, D L Stirewalt, S Meshinchi. (2010) Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia 24:5, 909-913
CrossRef305
Erin Dunbar, Anthony T. Yachnis. (2010) Glioma Diagnosis: Immunohistochemistry and Beyond. Advances in Anatomic Pathology 17:3, 187-201
CrossRef306
Jason T. Huse, Eric C. Holland. (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nature Reviews Cancer 10:5, 319-331
CrossRef307
Bastian Malzkorn, Marietta Wolter, Franziska Liesenberg, Michael Grzendowski, Kai Stühler, Helmut E. Meyer, Guido Reifenberger. (2010) Identification and Functional Characterization of microRNAs Involved in the Malignant Progression of Gliomas. Brain Pathology 20:3, 539-550
CrossRef308
Nader Pouratian, David Schiff. (2010) Management of Low-Grade Glioma. Current Neurology and Neuroscience Reports 10:3, 224-231
CrossRef309
Houtan Noushmehr, Daniel J. Weisenberger, Kristin Diefes, Heidi S. Phillips, Kanan Pujara, Benjamin P. Berman, Fei Pan, Christopher E. Pelloski, Erik P. Sulman, Krishna P. Bhat, Roel G.W. Verhaak, Katherine A. Hoadley, D. Neil Hayes, Charles M. Perou, Heather K. Schmidt, Li Ding, Richard K. Wilson, David Van Den Berg, Hui Shen, Henrik Bengtsson, Pierre Neuvial, Leslie M. Cope, Jonathan Buckley, James G. Herman, Stephen B. Baylin, Peter W. Laird, Kenneth Aldape. (2010) Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell 17:5, 510-522
CrossRef310
Thomas J. Hudson (Chairperson), Warwick Anderson, Axel Aretz, Anna D. Barker, Cindy Bell, Rosa R. Bernabé, M. K. Bhan, Fabien Calvo, Iiro Eerola, Daniela S. Gerhard, Alan Guttmacher, Mark Guyer, Fiona M. Hemsley, Jennifer L. Jennings, David Kerr, Peter Klatt, Patrik Kolar, Jun Kusuda, David P. Lane, Frank Laplace, Youyong Lu, Gerd Nettekoven, Brad Ozenberger, Jane Peterson, T.S. Rao, Jacques Remacle, Alan J. Schafer, Tatsuhiro Shibata, Michael R. Stratton, Joseph G. Vockley, Koichi Watanabe, Huanming Yang, Matthew M. F. Yuen, Bartha M. Knoppers (Leader), Martin Bobrow, Anne Cambon-Thomsen, Lynn G. Dressler, Stephanie O. M. Dyke, Yann Joly, Kazuto Kato, Karen L. Kennedy, Pilar Nicolás, Michael J. Parker, Emmanuelle Rial-Sebbag, Carlos M. Romeo-Casabona, Kenna M. Shaw, Susan Wallace, Georgia L. Wiesner, Nikolajs Zeps, Peter Lichter (Leader), Andrew V. Biankin, Christian Chabannon, Lynda Chin, Bruno Clément, Enrique de Alava, Françoise Degos, Martin L. Ferguson, Peter Geary, D. Neil Hayes, Thomas J. Hudson, Amber L. Johns, Arek Kasprzyk, Hidewaki Nakagawa, Robert Penny, Miguel A. Piris, Rajiv Sarin, Aldo Scarpa, Tatsuhiro Shibata, Marc van de Vijver, P. Andrew Futreal (Leader), Hiroyuki Aburatani, Mónica Bayés, David D.L. Bowtell, Peter J. Campbell, Xavier Estivill, Daniela S. Gerhard, Sean M. Grimmond, Ivo Gut, Martin Hirst, Carlos López-Otín, Partha Majumder, Marco Marra, John D. McPherson, Hidewaki Nakagawa, Zemin Ning, Xose S. Puente, Yijun Ruan, Tatsuhiro Shibata, Michael R. Stratton, Hendrik G. Stunnenberg, Harold Swerdlow, Victor E. Velculescu, Richard K. Wilson, Hong H. Xue, Liu Yang, Paul T. Spellman (Leader), Gary D. Bader, Paul C. Boutros, Peter J. Campbell, Paul Flicek, Gad Getz, Roderic Guigó, Guangwu Guo, David Haussler, Simon Heath, Tim J. Hubbard, Tao Jiang, Steven M. Jones, Qibin Li, Nuria López-Bigas, Ruibang Luo, Lakshmi Muthuswamy, B. F. Francis Ouellette, John V. Pearson, Xose S. Puente, Victor Quesada, Benjamin J. Raphael, Chris Sander, Tatsuhiro Shibata, Terence P. Speed, Lincoln D. Stein, Joshua M. Stuart, Jon W. Teague, Yasushi Totoki, Tatsuhiko Tsunoda, Alfonso Valencia, David A. Wheeler, Honglong Wu, Shancen Zhao, Guangyu Zhou, Lincoln D. Stein (Leader), Roderic Guigó, Tim J. Hubbard, Yann Joly, Steven M. Jones, Arek Kasprzyk, Mark Lathrop, Nuria López-Bigas, B. F. Francis Ouellette, Paul T. Spellman, Jon W. Teague, Gilles Thomas, Alfonso Valencia, Teruhiko Yoshida, Karen L. Kennedy (Leader), Myles Axton, Stephanie O. M. Dyke, P. Andrew Futreal, Daniela S. Gerhard, Chris Gunter, Mark Guyer, Thomas J. Hudson, John D. McPherson, Linda J. Miller, Brad Ozenberger, Kenna M. Shaw, Arek Kasprzyk (Leader), Lincoln D. Stein (Leader), Junjun Zhang, Syed A. Haider, Jianxin Wang, Christina K. Yung, Anthony Cross, Yong Liang, Saravanamuttu Gnaneshan, Jonathan Guberman, Jack Hsu, Martin Bobrow (Leader), Don R. C. Chalmers, Karl W. Hasel, Yann Joly, Terry S. H. Kaan, Karen L. Kennedy, Bartha M. Knoppers, William W. Lowrance, Tohru Masui, Pilar Nicolás, Emmanuelle Rial-Sebbag, Laura Lyman Rodriguez, Catherine Vergely, Teruhiko Yoshida, Sean M. Grimmond (Leader), Andrew V. Biankin, David D. L. Bowtell, Nicole Cloonan, Anna deFazio, James R. Eshleman, Dariush Etemadmoghadam, Brooke A. Gardiner, James G. Kench, Aldo Scarpa, Robert L. Sutherland, Margaret A. Tempero, Nicola J. Waddell, Peter J. Wilson, John D. McPherson (Leader), Steve Gallinger, Ming-Sound Tsao, Patricia A. Shaw, Gloria M. Petersen, Debabrata Mukhopadhyay, Lynda Chin, Ronald A. DePinho, Sarah Thayer, Lakshmi Muthuswamy, Kamran Shazand, Timothy Beck, Michelle Sam, Lee Timms, Vanessa Ballin, Youyong Lu (Leader), Jiafu Ji, Xiuqing Zhang, Feng Chen, Xueda Hu, Guangyu Zhou, Qi Yang, Geng Tian, Lianhai Zhang, Xiaofang Xing, Xianghong Li, Zhenggang Zhu, Yingyan Yu, Jun Yu, Huanming Yang, Mark Lathrop (Leader), Jörg Tost, Paul Brennan, Ivana Holcatova, David Zaridze, Alvis Brazma, Lars Egevad, Egor Prokhortchouk, Rosamonde Elizabeth Banks, Mathias Uhlén, Anne Cambon-Thomsen, Juris Viksna, Fredrik Ponten, Konstantin Skryabin, Michael R. Stratton (Leader), P. Andrew Futreal, Ewan Birney, Ake Borg, Anne-Lise Børresen-Dale, Carlos Caldas, John A. Foekens, Sancha Martin, Jorge S. Reis-Filho, Andrea L. Richardson, Christos Sotiriou, Hendrik G. Stunnenberg, Gilles Thomas, Marc van de Vijver, Laura van’t Veer, Fabien Calvo (Leader), Daniel Birnbaum, Hélène Blanche, Pascal Boucher, Sandrine Boyault, Christian Chabannon, Ivo Gut, Jocelyne D. Masson-Jacquemier, Mark Lathrop, Iris Pauporté, Xavier Pivot, Anne Vincent-Salomon, Eric Tabone, Charles Theillet, Gilles Thomas, Jörg Tost, Isabelle Treilleux, Fabien Calvo (Leader), Paulette Bioulac-Sage, Bruno Clément, Thomas Decaens, Françoise Degos, Dominique Franco, Ivo Gut, Marta Gut, Simon Heath, Mark Lathrop, Didier Samuel, Gilles Thomas, Jessica Zucman-Rossi, Peter Lichter (Leader), Roland Eils (Leader), Benedikt Brors, Jan O. Korbel, Andrey Korshunov, Pablo Landgraf, Hans Lehrach, Stefan Pfister, Bernhard Radlwimmer, Guido Reifenberger, Michael D. Taylor, Christof von Kalle, Partha P. Majumder (Leader), Rajiv Sarin, T. S. Rao, M. K. Bhan, Aldo Scarpa (Leader), Paolo Pederzoli, Rita T. Lawlor, Massimo Delledonne, Alberto Bardelli, Andrew V. Biankin, Sean M. Grimmond, Thomas Gress, David Klimstra, Giuseppe Zamboni, Tatsuhiro Shibata (Leader), Yusuke Nakamura, Hidewaki Nakagawa, Jun Kusuda, Tatsuhiko Tsunoda, Satoru Miyano, Hiroyuki Aburatani, Kazuto Kato, Akihiro Fujimoto, Teruhiko Yoshida, Elias Campo (Leader), Carlos López-Otín, Xavier Estivill, Roderic Guigó, Silvia de Sanjosé, Miguel A. Piris, Emili Montserrat, Marcos González-Díaz, Xose S. Puente, Pedro Jares, Alfonso Valencia, Heinz Himmelbaue, Victor Quesada, Silvia Bea, Michael R. Stratton (Leader), P. Andrew Futreal, Peter J. Campbell, Anne Vincent-Salomon, Andrea L. Richardson, Jorge S. Reis-Filho, Marc van de Vijver, Gilles Thomas, Jocelyne D. Masson-Jacquemier, Samuel Aparicio, Ake Borg, Anne-Lise Børresen-Dale, Carlos Caldas, John A. Foekens, Hendrik G. Stunnenberg, Laura van’t Veer, Douglas F. Easton, Paul T. Spellman, Sancha Martin, Anna D. Barker, Lynda Chin, Francis S. Collins, Carolyn C. Compton, Martin L. Ferguson, Daniela S. Gerhard, Gad Getz, Chris Gunter, Alan Guttmacher, Mark Guyer, D. Neil Hayes, Eric S. Lander, Brad Ozenberger, Robert Penny, Jane Peterson, Chris Sander, Kenna M. Shaw, Terence P. Speed, Paul T. Spellman, Joseph G. Vockley, David A. Wheeler, Richard K. Wilson, Thomas J. Hudson (Chairperson), Lynda Chin, Bartha M. Knoppers, Eric S. Lander, Peter Lichter, Lincoln D. Stein, Michael R. Stratton, Warwick Anderson, Anna D. Barker, Cindy Bell, Martin Bobrow, Wylie Burke, Francis S. Collins, Carolyn C. Compton, Ronald A. DePinho, Douglas F. Easton, P. Andrew Futreal, Daniela S. Gerhard, Anthony R. Green, Mark Guyer, Stanley R. Hamilton, Tim J. Hubbard, Olli P. Kallioniemi, Karen L. Kennedy, Timothy J. Ley, Edison T. Liu, Youyong Lu, Partha Majumder, Marco Marra, Brad Ozenberger, Jane Peterson, Alan J. Schafer, Paul T. Spellman, Hendrik G. Stunnenberg, Brandon J. Wainwright, Richard K. Wilson, Huanming Yang. (2010) International network of cancer genome projects. Nature 464:7291, 993-998
CrossRef311
O. Abdel-Wahab, R. L. Levine. (2010) Metabolism and the leukemic stem cell. Journal of Experimental Medicine 207:4, 677-680
CrossRef312
W. C. Chou, H. A. Hou, C. Y. Chen, J. L. Tang, M. Yao, W. Tsay, B. S. Ko, S. J. Wu, S. Y. Huang, S. C. Hsu, Y. C. Chen, Y. N. Huang, Y. C. Chang, F. Y. Lee, M. C. Liu, C. W. Liu, M. H. Tseng, C. F. Huang, H. F. Tien. (2010) Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 115:14, 2749-2754
CrossRef313
Jörg Felsberg, Marietta Wolter, Heike Seul, Britta Friedensdorf, Matthias Göppert, Michael C. Sabel, Guido Reifenberger. (2010) Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathologica 119:4, 501-507
CrossRef314
Daniel A. Tennant, Raúl V. Durán, Eyal Gottlieb. (2010) Targeting metabolic transformation for cancer therapy. Nature Reviews Cancer 10:4, 267-277
CrossRef315
Yukihiko Sonoda, Teiji Tominaga. (2010) 2-hydroxyglutarate accumulation caused by IDH mutation is involved in the formation of malignant gliomas. Expert Review of Neurotherapeutics 10:4, 487-489
CrossRef316
George P Atkinson, Susan E Nozell, Etty (Tika) N Benveniste. (2010) NF-κB and STAT3 signaling in glioma: targets for future therapies. Expert Review of Neurotherapeutics 10:4, 575-586
CrossRef317
Fonnet E. Bleeker, Nadia A. Atai, Simona Lamba, Ard Jonker, Denise Rijkeboer, Klazien S. Bosch, Wikky Tigchelaar, Dirk Troost, W. Peter Vandertop, Alberto Bardelli, Cornelis J. F. Noorden. (2010) The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathologica 119:4, 487-494
CrossRef318
RICARDO J. KOMOTAR, ROBERT M. STARKE, MICHAEL B. SISTI, E. SANDER CONNOLLY. (2010) IDH1 and IDH2 Mutations in Gliomas and the Associated Induction of Hypoxia-Inducible Factor and Production of 2-hydroxyglutarate. Neurosurgery 66:4, N20-N21
CrossRef319
S. Seidel, B. K. Garvalov, V. Wirta, L. von Stechow, A. Schanzer, K. Meletis, M. Wolter, D. Sommerlad, A. T. Henze, M. Nister, G. Reifenberger, J. Lundeberg, J. Frisen, T. Acker. (2010) A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 . Brain 133:4, 983-995
CrossRef320
Sandra Camelo-Piragua, Michael Jansen, Aniruddha Ganguly, J. ChulMin Kim, David N. Louis, Catherine L. Nutt. (2010) Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathologica 119:4, 509-511
CrossRef321
Jean-Pierre Bayley, Henricus PM Kunst, Alberto Cascon, Maria Lourdes Sampietro, José Gaal, Esther Korpershoek, Adolfo Hinojar-Gutierrez, Henri JLM Timmers, Lies H Hoefsloot, Mario A Hermsen, Carlos Suárez, A Karim Hussain, Annette HJT Vriends, Frederik J Hes, Jeroen C Jansen, Carli M Tops, Eleonora P Corssmit, Peter de Knijff, Jacques WM Lenders, Cor WRJ Cremers, Peter Devilee, Winand NM Dinjens, Ronald R de Krijger, Mercedes Robledo. (2010) SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. The Lancet Oncology 11:4, 366-372
CrossRef322
Eric C Cheung, Karen H Vousden. (2010) The role of p53 in glucose metabolism. Current Opinion in Cell Biology 22:2, 186-191
CrossRef323
Zachary J. Reitman, D. Williams Parsons, Hai Yan. (2010) IDH1 and IDH2: Not Your Typical Oncogenes. Cancer Cell 17:3, 215-216
CrossRef324
Patrick S. Ward, Jay Patel, David R. Wise, Omar Abdel-Wahab, Bryson D. Bennett, Hilary A. Coller, Justin R. Cross, Valeria R. Fantin, Cyrus V. Hedvat, Alexander E. Perl, Joshua D. Rabinowitz, Martin Carroll, Shinsan M. Su, Kim A. Sharp, Ross L. Levine, Craig B. Thompson. (2010) The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell 17:3, 225-234
CrossRef325
Michal Grzmil, Brian A. Hemmings. (2010) Deregulated signalling networks in human brain tumours. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1804:3, 476-483
CrossRef326
Viroj Wiwanitkit. (2010) Correspondence Regarding. Journal of Neuropathology and Experimental Neurology 69:3, 320
CrossRef327
Avaniyapuram Kannan Murugan, Ermal Bojdani, Mingzhao Xing. (2010) Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochemical and Biophysical Research Communications 393:3, 555-559
CrossRef328
Jochen Meyer, Stefan Pusch, Jörg Balss, David Capper, Wolf Mueller, Arne Christians, Christian Hartmann, Andreas von Deimling. (2010) PCR- and Restriction Endonuclease-Based Detection of IDH1 Mutations. Brain Pathology 20:2, 298-300
CrossRef329
Craig Horbinski. (2010) Authors' Reply. Journal of Neuropathology and Experimental Neurology 69:3, 320-321
CrossRef330
S. Gross, R. A. Cairns, M. D. Minden, E. M. Driggers, M. A. Bittinger, H. G. Jang, M. Sasaki, S. Jin, D. P. Schenkein, S. M. Su, L. Dang, V. R. Fantin, T. W. Mak. (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. Journal of Experimental Medicine 207:2, 339-344
CrossRef331
Masaya Nagaishi, Yoshihiro Tanaka, Kensho Iwatate, Hideaki Yokoo, Keisuke Ueki, Akio Hyodo, Yoichi Nakazato. (2010) Polar spongioblastoma: A high-grade glioma that does not contain the IDH1 mutation or 1p/19q LOH. Neuropathology
CrossRef332
Deric M. Park, Sith Sathornsumetee, Jeremy N. Rich. (2010) Medical oncology: Treatment and management of malignant gliomas. Nature Reviews Clinical Oncology 7:2, 75-77
CrossRef333
Green, Anthony, Beer, Philip, . (2010) Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms. New England Journal of Medicine 362:4, 369-370
Full Text334
Erika Check Hayden. (2010) Genomics boosts brain-cancer work. Nature 463:7279, 278-278
CrossRef335
Daniel J. Brat, Arie Perry. 2010. Astrocytic and Oligodendroglial Tumors. , 63-102.
CrossRef336
Kristopher T. Kahle, David Kozono, Kimberly Ng, Grace Hsieh, Pascal O. Zinn, Masayuki Nitta, Clark C. Chen. (2010) Functional genomics to explore cancer cell vulnerabilities. Neurosurgical FOCUS 28:1, E5
CrossRef337
Roel G.W. Verhaak, Katherine A. Hoadley, Elizabeth Purdom, Victoria Wang, Yuan Qi, Matthew D. Wilkerson, C. Ryan Miller, Li Ding, Todd Golub, Jill P. Mesirov, Gabriele Alexe, Michael Lawrence, Michael O'Kelly, Pablo Tamayo, Barbara A. Weir, Stacey Gabriel, Wendy Winckler, Supriya Gupta, Lakshmi Jakkula, Heidi S. Feiler, J. Graeme Hodgson, C. David James, Jann N. Sarkaria, Cameron Brennan, Ari Kahn, Paul T. Spellman, Richard K. Wilson, Terence P. Speed, Joe W. Gray, Matthew Meyerson, Gad Getz, Charles M. Perou, D. Neil Hayes. (2010) Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:1, 98-110
CrossRef338
Jesse J. Salk, Edward J. Fox, Lawrence A. Loeb. (2010) Mutational Heterogeneity in Human Cancers: Origin and Consequences. Annual Review of Pathology: Mechanisms of Disease 5:1, 51-75
CrossRef339
David Capper, Susanne WeiÃert, Jörg Balss, Antje Habel, Jochen Meyer, Diana Jäger, Ulrike Ackermann, Claudia Tessmer, Andrey Korshunov, Hanswalter Zentgraf, Christian Hartmann, Andreas Von Deimling. (2010) Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors. Brain Pathology 20:1, 245-254
CrossRef340
Christian Frezza, Daniel A. Tennant, Eyal Gottlieb. (2010) IDH1 Mutations in Gliomas: When an Enzyme Loses Its Grip. Cancer Cell 17:1, 7-9
CrossRef341
Lisa M DeAngelis. (2010) Neuro-oncology: new hope for patients with gliomas. The Lancet Neurology 9:1, 17-18
CrossRef342
Takao WATANABE, Kazunari YACHI, Takashi OHTA, Takao FUKUSHIMA, Atsuo YOSHINO, Yoichi KATAYAMA, Yui SHINOJIMA, Tadashi TERUI, Hiroki NAGASE. (2010) Aberrant Hypermethylation of Non-Promoter Zygote Arrest 1 (Zar1) in Human Brain Tumors. Neurologia medico-chirurgica 50:12, 1062-1069
CrossRef343
Riya Nagata, Ken Ikeda, Yoshikazu Nakamura, Yuichi Ishikawa, Ken Miura, Ryuta Sato, Yuji Kawase, Kiyokazu Kawabe, Yasuo Iwasaki. (2010) A Case of Gliomatosis Cerebri Mimicking Limbic Encephalitis: Malignant Transformation to Glioblastoma. Internal Medicine 49:13, 1307-1310
CrossRef344
Michelle Barbi de Moura, Lucas Santana dos Santos, Bennett Van Houten. (2010) Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environmental and Molecular MutagenesisNA-NA
CrossRef345
Linda B. C. Bralten, Nanne K. Kloosterhof, Lonneke A. M. Gravendeel, Andrea Sacchetti, Elza J. Duijm, Johan M. Kros, Martin J. van den Bent, Casper C. Hoogenraad, Peter A. E. Sillevis Smitt, Pim J. French. (2010) Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1 - SLC12A1 fusion gene. Genes, Chromosomes and CancerNA-NA
CrossRef346
Chihchen Chen, Johan Skog, Chia-Hsien Hsu, Ryan T. Lessard, Leonora Balaj, Thomas Wurdinger, Bob S. Carter, Xandra O. Breakefield, Mehmet Toner, Daniel Irimia. (2010) Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab on a Chip 10:4, 505
CrossRef347
Silke Götze, Marietta Wolter, Guido Reifenberger, Oliver Müller, Sonja Sievers. (2010) Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. International Journal of CancerNA-NA
CrossRef348
Kai-Jye Lou. (2009) IDH1: function follows form. Science-Business eXchange 2:48,
CrossRef349
Lenny Dang, David W. White, Stefan Gross, Bryson D. Bennett, Mark A. Bittinger, Edward M. Driggers, Valeria R. Fantin, Hyun Gyung Jang, Shengfang Jin, Marie C. Keenan, Kevin M. Marks, Robert M. Prins, Patrick S. Ward, Katharine E. Yen, Linda M. Liau, Joshua D. Rabinowitz, Lewis C. Cantley, Craig B. Thompson, Matthew G. Vander Heiden, Shinsan M. Su. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:7274, 739-744
CrossRef350
Craig Horbinski, Julia Kofler, Lindsey M. Kelly, Geoffrey H. Murdoch, Marina N. Nikiforova. (2009) Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues. Journal of Neuropathology and Experimental Neurology 68:12, 1319-1325
CrossRef351
Yukinari Kato, Genglin Jin, Chien-Tsun Kuan, Roger E. McLendon, Hai Yan, Darell D. Bigner. (2009) A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochemical and Biophysical Research Communications 390:3, 547-551
CrossRef352
Kamalakannan Palanichamy, Arnab Chakravarti. (2009) Combining drugs and radiotherapy: from the bench to the bedside. Current Opinion in Neurology 22:6, 625-632
CrossRef353
Patrick Y Wen, Alba A Brandes. (2009) Treatment of recurrent high-grade gliomas. Current Opinion in Neurology 22:6, 657-664
CrossRef354
Markus J Riemenschneider, Guido Reifenberger. (2009) Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches. Current Opinion in Neurology 22:6, 619-624
CrossRef355
Hiroko Ohgaki, Paul Kleihues. (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Science 100:12, 2235-2241
CrossRef356
Wolfgang Wick, Michael Weller. (2009) Classification and management of anaplastic gliomas. Current Opinion in Neurology 22:6, 650-656
CrossRef357
Sang Wook Park, Nak Gyun Chung, Ji Youn Han, Hyeon Seok Eom, Ji Youl Lee, Nam Jin Yoo, Sug Hyung Lee. (2009) Absence of IDH2 codon 172 mutation in common human cancers. International Journal of Cancer 125:10, 2485-2486
CrossRef358
François Ducray, Soufiane El Hallani, Ahmed Idbaih. (2009) Diagnostic and prognostic markers in gliomas. Current Opinion in Oncology 21:6, 537-542
CrossRef359
Joseph M. Piepmeier. (2009) The future of neuro-oncology. Acta Neurochirurgica 151:11, 1343-1348
CrossRef360
David Capper, Hanswalter Zentgraf, Jörg Balss, Christian Hartmann, Andreas Deimling. (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathologica 118:5, 599-601
CrossRef361
E. R. Mardis, R. K. Wilson. (2009) Cancer genome sequencing: a review. Human Molecular Genetics 18:R2, R163-R168
CrossRef362
Raffaele Addeo, M. Serena Santi, Salvatore Prete, Michele Caraglia. (2009) Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. Cancer Chemotherapy and Pharmacology 64:5, 863-866
CrossRef363
Susanne Schlisio. (2009) Neuronal apoptosis by prolyl hydroxylation: implication in nervous system tumours and the Warburg conundrum. Journal of Cellular and Molecular Medicine 13:10, 4104-4112
CrossRef364
Yukihiko Sonoda, Toshihiro Kumabe, Taigen Nakamura, Ryuta Saito, Masayuki Kanamori, Yoji Yamashita, Hiroyoshi Suzuki, Teiji Tominaga. (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Science 100:10, 1996-1998
CrossRef365
Christian Hartmann, Jochen Meyer, Jörg Balss, David Capper, Wolf Mueller, Arne Christians, Jörg Felsberg, Marietta Wolter, Christian Mawrin, Wolfgang Wick, Michael Weller, Christel Herold-Mende, Andreas Unterberg, Judith W. M. Jeuken, Peter Wesseling, Guido Reifenberger, Andreas Deimling. (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica 118:4, 469-474
CrossRef366
Maria Grazia Bruzzone, Marica Eoli, Valeria Cuccarini, Marina Grisoli, Lorella Valletta, Gaetano Finocchiaro. (2009) Genetic signature of adult gliomas and correlation with MRI features. Expert Review of Molecular Diagnostics 9:7, 709-720
CrossRef367
Mardis, Elaine R., Ding, Li, Dooling, David J., Larson, David E., McLellan, Michael D., Chen, Ken, Koboldt, Daniel C., Fulton, Robert S., Delehaunty, Kim D., McGrath, Sean D., Fulton, Lucinda A., Locke, Devin P., Magrini, Vincent J., Abbott, Rachel M., Vickery, Tammi L., Reed, Jerry S., Robinson, Jody S., Wylie, Todd, Smith, Scott M.Carmichael, Lynn, Eldred, James M.Harris, Christopher C., Walker, Jason, Peck, Joshua B., Du, Feiyu, Dukes, Adam F., Sanderson, Gabriel E., Brummett, Anthony M.Clark, EricMcMichael, Joshua F., Meyer, Rick J., Schindler, Jonathan K., Pohl, Craig S., Wallis, John W., Shi, Xiaoqi, Lin, Ling, Schmidt, Heather, Tang, Yuzhu, Haipek, Carrie, Wiechert, Madeline E., Ivy, Jolynda V., Kalicki, Joelle, Elliott, GlendoriaRies, Rhonda E., Payton, Jacqueline E., Westervelt, Peter, Tomasson, Michael H., Watson, Mark A., Baty, Jack, Heath, SharonShannon, William D., Nagarajan, Rakesh, Link, Daniel C., Walter, Matthew J., Graubert, Timothy A., DiPersio, John F., Wilson, Richard K., Ley, Timothy J., . (2009) Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome. New England Journal of Medicine 361:11, 1058-1066
Full Text368
Downing, James R., . (2009) Cancer Genomes — Continuing Progress. New England Journal of Medicine 361:11, 1111-1112
Full Text369
Andrey Korshunov, Jochen Meyer, David Capper, Arne Christians, Marc Remke, Hendrik Witt, Stefan Pfister, Andreas Deimling, Christian Hartmann. (2009) Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathologica 118:3, 401-405
CrossRef370
Matthias Holdhoff, D. Williams Parsons, Luis A. Diaz. (2009) Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. Journal of Neuro-Oncology 94:2, 297-297
CrossRef371
Benjamin Purow, David Schiff. (2009) Advances in the genetics of glioblastoma: are we reaching critical mass?. Nature Reviews Neurology 5:8, 419-426
CrossRef372
Jun Gu, Yanhong Liu, Athanassios P. Kyritsis, Melissa L. Bondy. (2009) Molecular epidemiology of primary brain tumors. Neurotherapeutics 6:3, 427-435
CrossRef373
David Schiff, Benjamin W. Purow. (2009) Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas. Nature Reviews Neurology 5:6, 303-304
CrossRef374
Takuya Watanabe, Anne Vital, Sumihito Nobusawa, Paul Kleihues, Hiroko Ohgaki. (2009) Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathologica 117:6, 653-656
CrossRef375
M. G. Vander Heiden, L. C. Cantley, C. B. Thompson. (2009) Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science 324:5930, 1029-1033
CrossRef376
(2009) IDH1 and IDH2 Mutations in Gliomas. New England Journal of Medicine 360:21, 2248-2249
Full Text377
Charles L. Sawyers. (2009) Finding and Drugging the Vulnerabilities of RAS-Dependent Cancers. Cell 137:5, 796-798
CrossRef378
S. Zhao, Y. Lin, W. Xu, W. Jiang, Z. Zha, P. Wang, W. Yu, Z. Li, L. Gong, Y. Peng, J. Ding, Q. Lei, K.-L. Guan, Y. Xiong. (2009) Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1 . Science 324:5924, 261-265
CrossRef379
(2009) Metabolic mutations in gliomas. Nature Reviews Cancer 9:4, 232-232
CrossRef380
Thompson, Craig B., . (2009) Metabolic Enzymes as Oncogenes or Tumor Suppressors. New England Journal of Medicine 360:8, 813-815
Full Text
- Letters
